US20020072780A1 - Method and apparatus for intentional impairment of gastric motility and /or efficiency by triggered electrical stimulation of the gastrointestinal tract with respect to the intrinsic gastric electrical activity - Google Patents
Method and apparatus for intentional impairment of gastric motility and /or efficiency by triggered electrical stimulation of the gastrointestinal tract with respect to the intrinsic gastric electrical activity Download PDFInfo
- Publication number
- US20020072780A1 US20020072780A1 US09/963,149 US96314901A US2002072780A1 US 20020072780 A1 US20020072780 A1 US 20020072780A1 US 96314901 A US96314901 A US 96314901A US 2002072780 A1 US2002072780 A1 US 2002072780A1
- Authority
- US
- United States
- Prior art keywords
- stimulation
- electrical
- recited
- gastric
- stimulator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/08—Arrangements or circuits for monitoring, protecting, controlling or indicating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36007—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation of urogenital or gastrointestinal organs, e.g. for incontinence control
Definitions
- the present invention relates to an implantable gastric electrical stimulator system that can be used to decrease gastric motility and/or gastric efficiency for the treatment of obesity. More particularly, the system employs an implantable electrical stimulator, one or a plurality of implantable stimulator leads (electrodes), and an external programmer, and an algorithm used to automatically control synchronized electrical stimulation frequency, interval, amplitude, or a combination of such parameters for treatment of obesity and other eating disorders.
- Obesity is a major health concern in western civilization. Surveys indicate that 33% of the population is overweight with the number increasing every year. Obesity is the second leading cause of preventable death in the United States. It is associated with several comorbidities that affect almost every body system. Some of these comorbidities are: hypertension, diabetes, coronary disease, breathing disorders, and musculoskeletal problems. It is estimated that the costs associated with obesity approach $70 billion per year.
- Gastroparesis is an adverse medical condition in which normal gastric function is impaired.
- Gastroparetic patients exhibit reduced gastric motility with accompanying symptoms of nausea and/or vomiting and gastric discomfort. They may complain of bloating or a premature or extended feeling of fullness (satiety).
- the condition results in reduced food intake (in portion and/or frequency) and subsequent weight loss.
- the condition may be associated with damage or neuropathy of the stomach enervation or damage or dystrophy of the stomach muscle with subsequent attenuated (in amplitude and/or frequency) peristaltic activity of the stomach muscles.
- the stomach is a complex organ of the digestive tract (alimentary canal) with the primary functions of dissolution, reduction, and motility of ingested food. These typical functions are accomplished through secretion of biochemical reagents to promote dissolution; kinetic mixing movements to reduce the particle size and promote mixing; and kinetic propulsive movements to move the chyme (solution of small food particles and biochemical reagents) into the intestines.
- the kinetic movements of the stomach are accomplished by organized/phased contractions of the stomach wall/smooth muscle.
- the neural control component refers to the intrinsic and extrinsic nerves innervating the stomach.
- the intrinsic nerves release various neurotransmitters and peptides that control contractions and motility. Studies indicate that the extrinsic nerves may influence the contractions by the release of modulative substances.
- the chemical control component refers to the various substances (neurotransmitters, neuromodulators and peptides) released from the nerve endings or endocrine-paracrine cells and glands of the stomach. These biochemical substances may act directly on the smooth muscle cell or on the nerves to modulate or control the occurrence of contractions and motility.
- the myogenic control component refers to small electrical oscillations of the smooth muscle cells related to polarization and depolarization of the smooth muscle cells.
- the myogenic activity is referred to as electrical control activity or slow waves.
- the slow wave is the underlying clock for peristaltic activity.
- Slow waves are omnipresent and typically occur at frequencies of 2-4 cycles per minute. All slow waves are not linked to contractions, but a normal peristaltic contraction must occur in synchrony with a slow wave.
- the slow wave (resulting from the cell membrane potential depolarization) provides the basic timing/interval and organization.
- the strength of the typical slow wave depolarization alone is not sufficient to exceed the excitation threshold required to initiate the smooth muscle contraction.
- a neural or chemical component must also be present to augment the myogenic activity. When a neural and/or chemical component is present, the depolarization strength exceeds the excitation threshold and a contraction occurs. (The contraction results in additional electrical activity referred to as electrical response activity or action potentials.)
- the contraction involves the circular and longitudinal muscle layers of the stomach wall. Contraction of the circular smooth muscle layer decreases the lumen diameter. Contraction of the longitudinal muscle layer decreases the length of the stomach and may serve to assist in expansion of the lumen adjacent to the contracted circular muscle layer and to propagate the contraction to the neighboring uncontracted segment of the circular muscle. Coordinated contraction between both muscle layers is necessary for peristaltic propagation.
- interference may impair the contraction and its associated kinetic function.
- the interference may be administered as any one or combination of the following:
- Additional methodologies may also accomplish the same ends, but may not be as easily applied, may require iterative or multiple applications or may be difficult to reverse. These additional methods include:
- Cigaina for “Process and Device for Treating Obesity and Syndromes Related to Motor Disorders of the Stomach of a Patient” issued Jun. 3, 1995, describes an implantable gastric electrical stimulator at the antrum area of the stomach which generates sequential electrical pulses to stimulate the entire stomach, thereby artificially altering the natural gastric motility to prevent emptying or to slow down food transit through the stomach.
- Cigaina however has the inherent disadvantage that it is a stimulation device solely, and does not incorporate on-demand stimulation other than that of manual cycling provided by magnetic application, which wastes energy by applying stimulation when it is not therapeutically required.
- Chen et al. additionally provides a sensor electrode or a stimulation electrode wherein the response of an organ to an electrical stimulation pulse is sensed for delivering stimulation to a plurality of electrodes to provide phased electrical stimulation.
- Chen et al. is specifically directed to phased stimulation that progresses through the plurality of electrodes located along the peristaltic flow path and specifically senses the response of the organ to the electrical stimulation. Chen does not address sensing of the intrinsic electrical activity for the purpose of applying therapy.
- the Bourgeois sensing circuitry inhibits therapy if a peristaltic wave is sensed and provides stimulation if it is not sensed. It does not apply therapy to impair gastric motility.
- U.S. Pat. No. 6,091,992 to Bourgeois for “Method and Apparatus for Electrical Stimulation of the Gastrointestinal Tract” issued Jul. 18, 2000, is similar to the '994 patent. It relates to provision of separate electrical pulse trains of differing parameters wherein the pulse trains are composed of a series of at least two pulses. The therapy is applied to promote gastric peristalsis.
- '955 addresses stimulation to promote gastric normalcy.
- the known prior art relates to (1) the provision of electrical stimulation (phased or unphased) without regard to intrinsic activity, or (2) the provision of electrical stimulation to induce normal peristalsis, or (3) the provision of electrical stimulation to counteract abnormal gastric activity.
- the present invention is directed to applying an implantable gastric stimulation (IGS) and lead system to sense intrinsic gastric electrical activity, identify that activity as normal or abnormal, and to apply electrical stimulation to the normal activity for the intended purpose of disrupting/disorganizing it.
- IGS implantable gastric stimulation
- lead system to sense intrinsic gastric electrical activity, identify that activity as normal or abnormal, and to apply electrical stimulation to the normal activity for the intended purpose of disrupting/disorganizing it.
- the present invention relates to a gastric simulator system and method for gastric stimulation of a patient employing an implantable gastric stimulator, which includes an information processor, electrical stimulation circuitry, electrical sensing circuitry, electrode switching circuitry, and telemetry circuitry.
- a remote programmer is provided to operate with the telemetry circuit of the implantable gastric stimulator for controlling the operation of the electrical stimulator circuit with the information processor.
- Leads are provided between the implantable gastric stimulator and the stomach wall of the patient for stimulation and/or sensing electrodes.
- the stimulation electrodes are provided for conveying electrical signals from the electrical stimulator circuit to the stomach wall of the patient, while the sensor electrodes are provided for communicating intrinsic gastric electrical activity information (from the stomach wall of the patient) via the electrical sensing circuitry to the information processor.
- the electrode switching circuitry allows the function and polarity of each electrode to be controlled by the information processor.
- FIG. 1 illustrates the components of the IGS system
- FIGS. 2A and 2B further illustrate the stimulation lead and the construction of the lead body
- FIG. 3 shows the placement of the electrodes in the stomach
- FIG. 4 shows a functional block diagram of a single channel IGS
- FIG. 5 shows a functional block diagram of a multi-channel
- FIG. 6 illustrates possible sensing “pairs” and stimulation vectors (“pairs”) of electrodes for a three electrode system
- FIG. 7 illustrates possible sensing “pairs” and stimulation vectors for a four electrode system
- FIG. 8 illustrates the progression of a normal gastric slow wave along the stomach
- FIG. 9 depicts the discernible features of a gastric slow wave
- FIG. 10 illustrates identification/classification of normal and abnormal gastric activity
- FIG. 11 depicts electrical stimulation at multiple sites
- FIG. 12 depicts electrical stimulation across a slow wave
- FIG. 13 depicts electrical stimulation with a spatial offset
- FIG. 14 depicts electrical stimulation with a spatial and temporal offset
- FIG. 15 depicts anticipatory electrical stimulation
- FIG. 16 illustrates the sensing history used to calculate the anticipated interval of the next slow wave
- FIG. 17 illustrates the timing of the anticipatory stimulation
- FIG. 18 illustrates decoupling stimulation (triggered by sensing at position C) applied at position E.
- the decoupling stimulus is intended to initiate an opposing contraction
- FIG. 19 illustrates proportional stimulation intended to disorganize 25% of the normal slow waves
- FIG. 20 illustrates proportional stimulation intended to disorganize 50% of the normal slow waves. An alternative embodiment would disrupt every other normal slow wave.
- the preferred embodiment of the invention consists of an implantable gastric stimulator (IGS), one or a plurality of implantable leads (two or more electrodes) that are electrically coupled to the stomach wall and the IGS, and an external programmer which can non-invasively communicate (bi-directionally) with the IGS via a radio frequency data link (see FIG. 1).
- IGS implantable gastric stimulator
- implantable leads two or more electrodes
- an external programmer which can non-invasively communicate (bi-directionally) with the IGS via a radio frequency data link (see FIG. 1).
- the external programmer is the interface between the physician (user) and the IGS. It consists of a transceiver to communicate with the IGS, a user interface (e.g., keyboard, tactile or soft buttons, display, and software) to provide a usable input/output method to the physician, and electronic circuitry and software to process the inputs or outputs to the appropriate format for either end (device or user).
- the programmer conveys information to the device and receives information from the device via a radio frequency data link. The information is conveyed as a string of data packets. In the preferred embodiment, an error checking algorithm would be utilized to determine the veracity of the string or packet.
- the implantable lead consists of a connector (proximal) end that interfaces (electrically and mechanically) to the IGS, a lead body (medial portion) that is electrically continuous between the connector (proximal) electrical terminals and the electrodes, and an electrode (distal) end that interfaces with the stomach wall (reference FIG. 2A).
- the connector end consists of one or a plurality of proximal electrical terminations, a means for insulation between the terminations and between the terminations and the surrounding environment, and a mechanical means for securing the connector to the IGS connection.
- the lead body (medial portion) consists of an electrically continuous path between the electrode(s) and proximal electrical terminations.
- the path is an elongated metallic coil.
- the lead body can have one or a plurality of coils. The coils are insulated from each other and from the surrounding environment by an insulating sheath(s).
- FIG. 2B depicts a typical lead body construction. Typically, each coil is connected to a specific proximal terminal (corresponding to an IGS input/output) and a specific electrode. An alternative configuration may have multiple electrodes connected to the same coil.
- the electrode (distal) end of the lead communicates electrically to the stomach wall.
- the electrodes are utilized in pairs to perform bipolar sensing and stimulation.
- the bipolar pairs are not required to be resident on the same implantable lead (multiple monopolar leads or a combination of monopolar and multipolar leads may be used instead).
- the electrodes should communicate with the circular layer of the stomach smooth muscle. This communication can be effected by superficial contact with the serosa, embedding the electrode intramuscularly (within the longitudinal or circular muscle), or by sub serosal placement.
- FIG. 3 depicts the electrodes embedded within the circular layer. The electrode size and configuration must consider the function, the implantation location, and the stimulation parameters to be utilized.
- a sensing electrode should have maximum surface area to acquire the intrinsic electrical signal.
- a stimulation electrode should have minimal surface area to concentrate the energy density for stimulation, but must also consider the effects of dissociation of the metal due to the stimulation pulse and due to ion imbalance.
- the gastric wall varies in thickness (depending on location) from 4-5 mm to greater than 1 cm with the circular and longitudinal layers comprising approximately half that thickness.
- the distal end contains the means for securely attaching the electrodes to the gastric wall.
- the fixation mechanism of the preferred embodiment is a pair of polymer tines that oppose each other and are located on either side of the electrode(s).
- FIG. 2A depicts the tine configuration at the distal end of the lead.
- An alternative fixation embodiment is to secure the lead to the gastric wall with a suture through the tissue and around an elastomer sleeve on the lead body.
- the IGS is a small, compact pulse generator. Externally, it consists of a hermetic housing and a means for electrically and mechanically connecting the lead to the internal electronics. Internally, the IGS contains electronic circuitry and a power supply (battery and/or rf energy coupling circuitry).
- the electronic circuitry consists of a microprocessor, electrical sensing (input) circuitry, electrical stimulation (output) circuitry, electrode switching circuitry, telemetry circuitry, and random access memory (reference FIG. 4).
- the IGS may have multiple sensing and/or stimulation circuits (channels) to provide more optimum sensing and stimulation to differing areas of the gastric system (reference FIG. 5).
- the microprocessor is an integrated circuit that serves as an information processor that controls the IGS functions, performance, and analyses (if any). It receives inputs from the telemetry circuitry, the sensing circuitry, the RAM, and from internal functional checking. Depending upon the programming and the inputs, the microprocessor controls outputs to the telemetry circuitry, the stimulation circuitry, the RAM, and the electrode switching circuitry. The processor controls the basic timing and routing of the inputs and the output sequencing and parameters.
- the sensing circuitry receives signals from the intrinsic gastric electrical activity via the selected sensing electrodes of the lead(s).
- the sensing input is utilized to classify the intrinsic gastric activity and as the trigger for the stimulation output.
- the sensing circuitry filters and amplifies the intrinsic signal and conveys it to the microprocessor.
- the sensing circuitry may employ a neural network approach to assist in the classification of the intrinsic gastric activity.
- the selection of the sensing electrodes, the timing of the sensing, and degree of amplification is controlled by the microprocessor and is programmable (via the telemetry circuitry).
- the stimulation circuitry provides the electrical pulses employed for stimulation.
- the stimulation circuitry may invoke either a constant current approach or a constant voltage approach.
- the stimulation circuitry will provide pulses of programmable amplitude, frequency (pulses per second), and pulse width.
- An alternative embodiment entails the use of switching between individual capacitors in an array (switch cap technology) to provide adjacent or overlapping pulses of narrow width to achieve a continuous (or near continuous) pulse of a wider width.
- the stimulation circuitry is controlled by the microprocessor and is programmable.
- the electrode switching circuitry establishes the function of each electrode and the polarity of the electrode.
- the electrode switching circuitry will enable a pair of electrodes to be used for sensing, and a pair or pairs of electrodes to be used for stimulation.
- FIGS. 6 and 7 depict possible sensing configurations (“pairs”) and possible stimulation vectors for a three and a four electrode system. The stimulation and sensing may utilize the same electrodes.
- the electrode switching circuitry can change the polarity of the stimulation electrodes to create multi-phasic pulses, alternating polarity between pulses or a series of pulses, and different stimulation vectors.
- the switching circuitry can enable different pairs of sensing electrodes to sample gastric electrical activity at various sensing locations or along different vectors. Complex sensing patterns can be invoked to differentiate slow wave propagation direction and intervals. The switching circuitry may also include compensation (to offset internal leakage currents across the switches involved in sensing) and blanking to prevent stimulation pulses from saturating the sense amplifiers.
- the switching circuitry is controlled by the microprocessor and is programmable. Complex switching schemes can be stored in RAM and be activated as a program. The switching software would be designed to ensure that each configuration would have at least one bipolar pair to complete the electrical circuit.
- the telemetry circuitry consists of an antenna and a transceiver.
- the circuitry may also include a telemetry buffer to accommodate large data transactions.
- the telemetry circuit transmits and receives pulses to and from the programmer.
- the circuitry may employ amplitude modulation, frequency modulation, or pulsed modulation at radio frequencies.
- the telemetry would have a range of several inches to allow for deep implantation of the IGS.
- the telemetry string would utilize an initiation protocol to establish two way communication, an identity packet to provide device/programmer identification, multiple information or programming packets to communicate the requisite data, error checking of the packets (cyclic redundancy checking or check sums) to ensure accuracy of the information, and a termination protocol to signal the end of the string.
- the incoming string would be processed by the microprocessor to set the parameters of the IGS.
- the outgoing string would basically acknowledge that the incoming string was accepted, confirm IGS settings or provide raw data/information for processing by the external programmer.
- the RAM is used to store information and programs for the IGS.
- the RAM receives the sensed information about the intrinsic gastric activity from the microprocessor, analyzes that information to determine if the activity is normal according to a selected algorithm(s), and provides that analysis output to the microprocessor to initiate the therapy in accordance with the particular programming selected.
- Multiple programs may be stored in RAM to establish specific profiles of IGS activation, response, and performance.
- the RAM may also be used to store various parameters that indicate device performance, gastric activities, and therapies administered.
- the electrodes of the lead(s) would be implanted (laparoscopically or through an open incision) in or on the gastric wall for communication with the circular layer of the gastric smooth muscle (reference FIG. 3). Since the lower portion of the stomach is primarily responsible for solids mixing and motility, the preferred location of the electrodes is the antrum, along the lesser curvature. The lesser curvature is preferable because it does not distend as much as the greater curvature and offers a more stable position. After the lead is secured, the IGS would be connected to the lead(s) and implanted in a subcutaneous or sub-fascial pocket in the patient's abdomen.
- FIG. 8 depicts the progression of a normal slow wave along the stomach from position A through position F.
- the normal activity has pulse amplitudes, pulse widths, and frequency (intervals) that are discernible from abnormal activity.
- FIG. 9 depicts the discernible parameters that can be utilized to identify/classify the slow wave.
- the depolarization of the cells will impart an electrical potential on that electrode (differentially compared to a second electrode in an area not undergoing depolarization). If the two electrodes have been programmed to serve as sensing electrodes, the electric potential is conveyed to the sensing circuitry. There it is filtered and amplified and presented to the information processor.
- the information processor (in conjunction with any RAM program/algorithm) identifies/classifies the activity as normal or abnormal.
- FIG. 10 depicts a string of gastric activity and the potential classification of the waves. If identified as normal, the information processor initiates stimulation as per the programmed parameters. If classified as abnormal, the microprocessor re-initiates sensing. Certain parameters of the intrinsic signal and stimulation are logged into RAM for history and for use in other algorithms.
- An alternative embodiment of the invention analyzes the frequency components of the sensed signal for evidence of electrical response activity resulting from a contraction. If the signal contains frequencies that are associated with a contraction, a stronger type of stimulation is invoked to disrupt/disorganize or decouple the contraction.
- the preferred embodiment may invoke one or multiple stimulation therapies that are dependent upon the activity sensed and the programmed therapeutic scheme.
- the stimulation may use electrical pulse trains of equally alternating polarity, electrical pulse trains of asymmetrically alternating polarity, and multiphasic pulses of equal or unequal phase widths.
- the stimulation may be delivered at a single or a plurality of sites.
- FIG. 11 depicts stimulation at multiple (two) sites. Additionally the stimulation vector can be switched (at any point) between any single pair of electrodes or plurality of electrodes providing that at least one bipolar pair is selected (reference FIGS. 6 and 7).
- the stimulation schemes are described as follows:
- Stimulation across a slow wave occurs when the stimulation is applied between electrodes that lie on opposite sides of the slow wave. It is designed to depolarize cells prior to the wave induced depolarization. This will make the cells refractory to the wave and create an attenuation of the slow wave in the area of stimulation. Stimulation across the wave has a disadvantage in that some of the cells involved are already depolarized (as a result of the wave) and energy is wasted on those cells.
- Stimulation in advance (spatial offset) of propagation affords the advantage of only involving cells that are not part of the wave.
- the disadvantage is that the degree (length and direction/orientation) of the spatial offset must be considered to ensure that cell repolarization does not occur before the wave arrives. It may require relatively fixed configurations of electrodes placed in relation to the propagation path.
- Stimulation in advance (spatial and temporal offsets) of propagation (FIG. 14).
- Stimulation in advance of wave propagation with a temporal and a spatial offset involves sensing at one location and stimulation at a second location with a programmable delay to ensure that the cells do not repolarize before the wave arrives. It affords the advantage of a spatial offset and does not require precise electrode orientations to achieve the same ends.
- Anticipatory stimulation involves sensing between a pair of electrodes and delaying the stimulation until just prior to the next normal wave is anticipated.
- the stimulation may be applied to the sensing electrodes or any set of electrodes upstream from the sensing electrodes.
- the amount of delay is calculated from the history of normal intervals derived from the sensing identification and parameter storage.
- FIG. 16 depicts a running history used to calculate the expected interval timing until the next normal slow wave. The calculation would involve averaging a running history of normal intervals and subtracting a small time interval from that average.
- FIG. 17 depicts the anticipatory stimulation interval timing.
- Decoupling stimulation involves sensing a peristaltic contraction at one location and strong stimulation at a second location to invoke a competing contraction that would propagate towards and away from the intrinsic contraction. Where the two contractions meet, they would tend to cancel each other. The advancing invoked contraction would not have the volume of chyme because it would precede the intrinsic movement and the efficiency of the gastric motility would be reduced.
- Ectopic stimulation involves overriding the intrinsic electrical activity by application of strong stimulation at an interval that is shorter than the intrinsic interval and at a location that does not afford a natural progression of the motility. The preferred location is on the gastric antrum close to the pylorus such that the majority of any propagation would be retrograde.
- Combined nerve and gastric stimulation involves application of any of the previously listed therapy schemes with specific stimulation intended to suppress, block, or desensitize the enervation of the stomach.
- the stimulation could be a combination of pulse trains having neuro and muscular components or separate channels dedicated to the specific neural or muscular waveforms.
- Proportional stimulation is a modulator of any or all of the previous stimulation schemes (except ectopic stimulation).
- proportional stimulation the disruptive, disorganizing, or decoupling stimulation is applied to a programmable percentage of the qualifying (normal) intrinsic activity.
- FIGS. 19 and 20 depict disorganization of 25% and 50% of the normal slow waves. (An alternative embodiment of FIG. 20 is disorganization of every other normal slow wave.) This type of stimulation allows the physician to modulate the intrinsic activity and still preserve some normal function.
- proportional stimulation will be less frequent due to the decreased quantity of qualifying normal waves.
Abstract
A sensor based gastric stimulator system and method for gastric stimulation of a patient employing an implantable gastric stimulator, which includes an information processor, an electrical stimulator circuit, and telemetry circuitry. The implantable stimulator senses intrinsic, gastric electrical activity (slow waves and/or peristaltic waves) and delivers electrical stimulation to intentionally disrupt or disorganize that activity. The stimulation is triggered by (tracks) normal gastric electrical activity and can be delivered with a spatial offset to anticipate the propagating gastric electrical activity or may be delayed temporally to anticipate the next propagating slow or peristaltic wave. The stimulator may be programmed to disrupt/disorganize all or a percentage of the intrinsic, normal gastric electrical activity. The programmer (via radio frequency data link) may non-invasively program stimulation parameters and intervals. The stimulator may provide stimulation to one or a plurality of stimulation sites and may incorporate one or a plurality of independently programmable sensing and/or stimulation channels. The information processor of the implantable gastric stimulator uses the gastric stimulation information from the non-electrode sensor for determining periods or windows of susceptibility for application of the electrical signals conveyed with the stimulation electrode for conveying electrical signals from the electrical stimulator circuit to the stomach wall of the patient.
Description
- This application claims benefit of U.S. Provisional Application No. 60/235,660, filed Sep. 26, 2000.
- 1. Field of the Invention
- The present invention relates to an implantable gastric electrical stimulator system that can be used to decrease gastric motility and/or gastric efficiency for the treatment of obesity. More particularly, the system employs an implantable electrical stimulator, one or a plurality of implantable stimulator leads (electrodes), and an external programmer, and an algorithm used to automatically control synchronized electrical stimulation frequency, interval, amplitude, or a combination of such parameters for treatment of obesity and other eating disorders.
- 2. Description of the Related Art
- Obesity is a major health concern in western civilization. Surveys indicate that 33% of the population is overweight with the number increasing every year. Obesity is the second leading cause of preventable death in the United States. It is associated with several comorbidities that affect almost every body system. Some of these comorbidities are: hypertension, diabetes, coronary disease, breathing disorders, and musculoskeletal problems. It is estimated that the costs associated with obesity approach $70 billion per year.
- Multiple factors contribute to obesity, but the two major factors are physical inactivity and overeating. Existing therapies include diet, exercise, appetite suppressive drugs, metabolism enhancing drugs, surgical restriction of the gastric tract, and surgical modification of the gastric tract. Efficacy of these therapies range from little or no weight loss up to weight loss approaching 50% of initial body weight.
- Gastroparesis is an adverse medical condition in which normal gastric function is impaired. Gastroparetic patients exhibit reduced gastric motility with accompanying symptoms of nausea and/or vomiting and gastric discomfort. They may complain of bloating or a premature or extended feeling of fullness (satiety). Typically, the condition results in reduced food intake (in portion and/or frequency) and subsequent weight loss. Physiologically, the condition may be associated with damage or neuropathy of the stomach enervation or damage or dystrophy of the stomach muscle with subsequent attenuated (in amplitude and/or frequency) peristaltic activity of the stomach muscles. Some studies indicate that it is also associated with dysrhythmias of the stomach.
- An examination of the symptomology and consequences of gastroparesis reveals some effects that could be beneficial as a therapy for obesity, if they could be mediated and modulated. This disclosure sets forth a class of implantable electrical device(s) that can potentially effect a mild, reversible form of gastroparesis by inducing electrophysiological disorganization or disruption in the normal stomach motility.
- The stomach is a complex organ of the digestive tract (alimentary canal) with the primary functions of dissolution, reduction, and motility of ingested food. These typical functions are accomplished through secretion of biochemical reagents to promote dissolution; kinetic mixing movements to reduce the particle size and promote mixing; and kinetic propulsive movements to move the chyme (solution of small food particles and biochemical reagents) into the intestines. The kinetic movements of the stomach are accomplished by organized/phased contractions of the stomach wall/smooth muscle.
- Normal contractions of the stomach are the result of three control components: neural activity, chemical activity, and myogenic activity.
- The neural control component refers to the intrinsic and extrinsic nerves innervating the stomach. The intrinsic nerves release various neurotransmitters and peptides that control contractions and motility. Studies indicate that the extrinsic nerves may influence the contractions by the release of modulative substances.
- The chemical control component refers to the various substances (neurotransmitters, neuromodulators and peptides) released from the nerve endings or endocrine-paracrine cells and glands of the stomach. These biochemical substances may act directly on the smooth muscle cell or on the nerves to modulate or control the occurrence of contractions and motility.
- The myogenic control component refers to small electrical oscillations of the smooth muscle cells related to polarization and depolarization of the smooth muscle cells. The myogenic activity is referred to as electrical control activity or slow waves.
- The slow wave is the underlying clock for peristaltic activity. Slow waves are omnipresent and typically occur at frequencies of 2-4 cycles per minute. All slow waves are not linked to contractions, but a normal peristaltic contraction must occur in synchrony with a slow wave.
- To initiate normal peristaltic contractions, multiple control means must be present. The slow wave (resulting from the cell membrane potential depolarization) provides the basic timing/interval and organization. However, the strength of the typical slow wave depolarization alone is not sufficient to exceed the excitation threshold required to initiate the smooth muscle contraction. A neural or chemical component must also be present to augment the myogenic activity. When a neural and/or chemical component is present, the depolarization strength exceeds the excitation threshold and a contraction occurs. (The contraction results in additional electrical activity referred to as electrical response activity or action potentials.)
- However, initiating the contraction is only part of the peristaltic activity. To be physiologically effective (efficiently reduce, mix and/or propulse the stomach contents), the contraction must propagate in an organized, phased manner in three dimensions and in time (across and/or along the various muscle layers of the stomach).
- Typically, the contraction involves the circular and longitudinal muscle layers of the stomach wall. Contraction of the circular smooth muscle layer decreases the lumen diameter. Contraction of the longitudinal muscle layer decreases the length of the stomach and may serve to assist in expansion of the lumen adjacent to the contracted circular muscle layer and to propagate the contraction to the neighboring uncontracted segment of the circular muscle. Coordinated contraction between both muscle layers is necessary for peristaltic propagation.
- Intentional interference with any or all of the three control components and/or the coordination of the contraction propagation may impair the contraction and its associated kinetic function. Electrophysiologically, the interference may be administered as any one or combination of the following:
- (a) electrical stimulation that induces asynchronous depolarization of individual cells or small groups of cells just prior to (spatially or temporally) or during a slow wave or peristaltic wave creating disorganization/attenuation of the wave;
- (b) electrical stimulation that induces synchronous depolarization of a large area of cells prior to a slow wave or peristaltic wave creating an area that is refractory to the wave (may also induce a contraction);
- (c) persistent electrical stimulation of the stomach nerves creating a neural desensitization, suppression or blocking of the stimulated area;
- (d) electrical stimulation that entrains the slow wave at a frequency greater than 4 cpm creating a tachygastria condition so that peristalsis does not occur;
- (e) electrical stimulation that entrains the slow wave at a frequency that competes with the intrinsic frequency but originates at a different location(s) creating competing ectopic waves; and
- (f) temporally or spatially segregated, directional electrical stimulation of the individual muscle layers creating decoupling of the peristaltic coordination.
- Additional methodologies may also accomplish the same ends, but may not be as easily applied, may require iterative or multiple applications or may be difficult to reverse. These additional methods include:
- (a) creation of gastric smooth muscle lesions by ablative techniques (radio frequency, microwave, cryogenic) to lessen the contractility of the muscle or to change the contraction vector to a less efficient direction/sequence; and
- (b) administration of precise doses and patterns of intra-muscular paralytic agents (e.g., botulism toxin, curare, etc.) to prevent the affected areas from contracting and/or to force a contraction along a specific less efficient path.
- These items are discussed in separate disclosures. This disclosure will focus on the electrophysiological means of impairment.
- Electrical stimulation of the stomach and other portions of the gastric intestinal tract has been experimented with for some time. Most of the experimentation has been oriented toward improving the gastric emptying usually by attempting to speed up or strengthen/reinforce the peristaltic activity.
- U.S. Pat. No. 5,423,872 to Cigaina for “Process and Device for Treating Obesity and Syndromes Related to Motor Disorders of the Stomach of a Patient” issued Jun. 3, 1995, describes an implantable gastric electrical stimulator at the antrum area of the stomach which generates sequential electrical pulses to stimulate the entire stomach, thereby artificially altering the natural gastric motility to prevent emptying or to slow down food transit through the stomach. Cigaina however has the inherent disadvantage that it is a stimulation device solely, and does not incorporate on-demand stimulation other than that of manual cycling provided by magnetic application, which wastes energy by applying stimulation when it is not therapeutically required.
- U.S. Pat. No. 5,690,691 to Chen et al. for “Gastro-intestinal Pacemaker Having Phased Multi-Point Stimulation” issued Nov. 25, 1997, describes a portable or implantable gastric pacemaker employing a number of electrodes along the greater curvature of the stomach for delivering phased electrical stimulation at different locations to accelerate or attenuate peristaltic movement in the GI tract. Chen et al. additionally provides a sensor electrode or a stimulation electrode wherein the response of an organ to an electrical stimulation pulse is sensed for delivering stimulation to a plurality of electrodes to provide phased electrical stimulation. However, Chen et al. is specifically directed to phased stimulation that progresses through the plurality of electrodes located along the peristaltic flow path and specifically senses the response of the organ to the electrical stimulation. Chen does not address sensing of the intrinsic electrical activity for the purpose of applying therapy.
- U.S. Pat. No. 5,836,994 to Bourgeois for “Method and Apparatus for Electrical Stimulation of the Gastrointestinal Tract” issued Nov. 17, 1998, describes an implantable gastric stimulator which incorporates direct sensing of the intrinsic gastric electrical activity by one or more sensors of predetermined frequency bandwidth for application or cessation of stimulation based on the amount of sensed activity. The Bourgeois sensing circuitry inhibits therapy if a peristaltic wave is sensed and provides stimulation if it is not sensed. It does not apply therapy to impair gastric motility.
- U.S. Pat. No. 6,091,992 to Bourgeois for “Method and Apparatus for Electrical Stimulation of the Gastrointestinal Tract” issued Jul. 18, 2000, is similar to the '994 patent. It relates to provision of separate electrical pulse trains of differing parameters wherein the pulse trains are composed of a series of at least two pulses. The therapy is applied to promote gastric peristalsis.
- U.S. Pat. No. 6,104,955 to Bourgeois for “Method and Apparatus for Electrical Stimulation of the Gastrointestinal Tract” issued Aug. 15, 2000, relates to a gastric stimulator with reversion to a sensing mode to determine the intrinsic slow wave interval to prevent stimulation when the gastric tract is in inter-digestive phases. Like the previous Bourgeois patents, '955 addresses stimulation to promote gastric normalcy.
- U.S. Pat. No. 5,861,014 to Familoni for “Method and Apparatus for Sensing a Stimulating Gastrointestinal Tract On-Demand” issued Jan. 19, 1999, relates to an implantable gastric stimulator for sensing abnormal electrical activity of the gastrointestinal tract so as to provide electrical stimulation for a preset time period or for the duration of the abnormal electrical activity to treat gastric rhythm abnormalities. Familoni also addresses recording of abnormal activity for a preset time period, but does not address altering of a normal gastric activity to achieve a variable result such as treatment for obesity. It does not apply therapy to disrupt normal gastric activity.
- Accordingly, the known prior art relates to (1) the provision of electrical stimulation (phased or unphased) without regard to intrinsic activity, or (2) the provision of electrical stimulation to induce normal peristalsis, or (3) the provision of electrical stimulation to counteract abnormal gastric activity.
- Thus, the prior art does not address the provision of electrical stimulation with regards to intrinsic gastric electrical activity for the intended purpose of disrupting normal, intrinsic gastric activity.
- The present invention is directed to applying an implantable gastric stimulation (IGS) and lead system to sense intrinsic gastric electrical activity, identify that activity as normal or abnormal, and to apply electrical stimulation to the normal activity for the intended purpose of disrupting/disorganizing it.
- Briefly summarized, the present invention relates to a gastric simulator system and method for gastric stimulation of a patient employing an implantable gastric stimulator, which includes an information processor, electrical stimulation circuitry, electrical sensing circuitry, electrode switching circuitry, and telemetry circuitry. A remote programmer is provided to operate with the telemetry circuit of the implantable gastric stimulator for controlling the operation of the electrical stimulator circuit with the information processor. Leads are provided between the implantable gastric stimulator and the stomach wall of the patient for stimulation and/or sensing electrodes. The stimulation electrodes are provided for conveying electrical signals from the electrical stimulator circuit to the stomach wall of the patient, while the sensor electrodes are provided for communicating intrinsic gastric electrical activity information (from the stomach wall of the patient) via the electrical sensing circuitry to the information processor. The electrode switching circuitry allows the function and polarity of each electrode to be controlled by the information processor.
- FIG. 1 illustrates the components of the IGS system;
- FIGS. 2A and 2B further illustrate the stimulation lead and the construction of the lead body;
- FIG. 3 shows the placement of the electrodes in the stomach;
- FIG. 4 shows a functional block diagram of a single channel IGS;
- FIG. 5 shows a functional block diagram of a multi-channel;
- FIG. 6 illustrates possible sensing “pairs” and stimulation vectors (“pairs”) of electrodes for a three electrode system;
- FIG. 7 illustrates possible sensing “pairs” and stimulation vectors for a four electrode system;
- FIG. 8 illustrates the progression of a normal gastric slow wave along the stomach;
- FIG. 9 depicts the discernible features of a gastric slow wave;
- FIG. 10 illustrates identification/classification of normal and abnormal gastric activity;
- FIG. 11 depicts electrical stimulation at multiple sites;
- FIG. 12 depicts electrical stimulation across a slow wave;
- FIG. 13 depicts electrical stimulation with a spatial offset;
- FIG. 14 depicts electrical stimulation with a spatial and temporal offset;
- FIG. 15 depicts anticipatory electrical stimulation;
- FIG. 16 illustrates the sensing history used to calculate the anticipated interval of the next slow wave;
- FIG. 17 illustrates the timing of the anticipatory stimulation;
- FIG. 18 illustrates decoupling stimulation (triggered by sensing at position C) applied at position E. The decoupling stimulus is intended to initiate an opposing contraction;
- FIG. 19 illustrates proportional stimulation intended to disorganize 25% of the normal slow waves; and
- FIG. 20 illustrates proportional stimulation intended to disorganize 50% of the normal slow waves. An alternative embodiment would disrupt every other normal slow wave.
- The preferred embodiment of the invention consists of an implantable gastric stimulator (IGS), one or a plurality of implantable leads (two or more electrodes) that are electrically coupled to the stomach wall and the IGS, and an external programmer which can non-invasively communicate (bi-directionally) with the IGS via a radio frequency data link (see FIG. 1).
- The external programmer is the interface between the physician (user) and the IGS. It consists of a transceiver to communicate with the IGS, a user interface (e.g., keyboard, tactile or soft buttons, display, and software) to provide a usable input/output method to the physician, and electronic circuitry and software to process the inputs or outputs to the appropriate format for either end (device or user). The programmer conveys information to the device and receives information from the device via a radio frequency data link. The information is conveyed as a string of data packets. In the preferred embodiment, an error checking algorithm would be utilized to determine the veracity of the string or packet.
- The implantable lead consists of a connector (proximal) end that interfaces (electrically and mechanically) to the IGS, a lead body (medial portion) that is electrically continuous between the connector (proximal) electrical terminals and the electrodes, and an electrode (distal) end that interfaces with the stomach wall (reference FIG. 2A).
- The connector end consists of one or a plurality of proximal electrical terminations, a means for insulation between the terminations and between the terminations and the surrounding environment, and a mechanical means for securing the connector to the IGS connection.
- The lead body (medial portion) consists of an electrically continuous path between the electrode(s) and proximal electrical terminations. Typically, the path is an elongated metallic coil. The lead body can have one or a plurality of coils. The coils are insulated from each other and from the surrounding environment by an insulating sheath(s). FIG. 2B depicts a typical lead body construction. Typically, each coil is connected to a specific proximal terminal (corresponding to an IGS input/output) and a specific electrode. An alternative configuration may have multiple electrodes connected to the same coil.
- The electrode (distal) end of the lead communicates electrically to the stomach wall. In the preferred embodiment, the electrodes are utilized in pairs to perform bipolar sensing and stimulation. However, also in the preferred embodiment, the bipolar pairs are not required to be resident on the same implantable lead (multiple monopolar leads or a combination of monopolar and multipolar leads may be used instead). The electrodes should communicate with the circular layer of the stomach smooth muscle. This communication can be effected by superficial contact with the serosa, embedding the electrode intramuscularly (within the longitudinal or circular muscle), or by sub serosal placement. FIG. 3 depicts the electrodes embedded within the circular layer. The electrode size and configuration must consider the function, the implantation location, and the stimulation parameters to be utilized. A sensing electrode should have maximum surface area to acquire the intrinsic electrical signal. A stimulation electrode should have minimal surface area to concentrate the energy density for stimulation, but must also consider the effects of dissociation of the metal due to the stimulation pulse and due to ion imbalance. Likewise, the gastric wall varies in thickness (depending on location) from 4-5 mm to greater than 1 cm with the circular and longitudinal layers comprising approximately half that thickness. Additionally, the distal end contains the means for securely attaching the electrodes to the gastric wall. The fixation mechanism of the preferred embodiment is a pair of polymer tines that oppose each other and are located on either side of the electrode(s). FIG. 2A depicts the tine configuration at the distal end of the lead. An alternative fixation embodiment is to secure the lead to the gastric wall with a suture through the tissue and around an elastomer sleeve on the lead body.
- The IGS is a small, compact pulse generator. Externally, it consists of a hermetic housing and a means for electrically and mechanically connecting the lead to the internal electronics. Internally, the IGS contains electronic circuitry and a power supply (battery and/or rf energy coupling circuitry).
- In the preferred embodiment, the electronic circuitry consists of a microprocessor, electrical sensing (input) circuitry, electrical stimulation (output) circuitry, electrode switching circuitry, telemetry circuitry, and random access memory (reference FIG. 4). In an alternative embodiment, the IGS may have multiple sensing and/or stimulation circuits (channels) to provide more optimum sensing and stimulation to differing areas of the gastric system (reference FIG. 5).
- The microprocessor is an integrated circuit that serves as an information processor that controls the IGS functions, performance, and analyses (if any). It receives inputs from the telemetry circuitry, the sensing circuitry, the RAM, and from internal functional checking. Depending upon the programming and the inputs, the microprocessor controls outputs to the telemetry circuitry, the stimulation circuitry, the RAM, and the electrode switching circuitry. The processor controls the basic timing and routing of the inputs and the output sequencing and parameters.
- The sensing circuitry receives signals from the intrinsic gastric electrical activity via the selected sensing electrodes of the lead(s). The sensing input is utilized to classify the intrinsic gastric activity and as the trigger for the stimulation output. The sensing circuitry filters and amplifies the intrinsic signal and conveys it to the microprocessor. The sensing circuitry may employ a neural network approach to assist in the classification of the intrinsic gastric activity. The selection of the sensing electrodes, the timing of the sensing, and degree of amplification is controlled by the microprocessor and is programmable (via the telemetry circuitry).
- The stimulation circuitry provides the electrical pulses employed for stimulation. The stimulation circuitry may invoke either a constant current approach or a constant voltage approach. In the preferred embodiment, the stimulation circuitry will provide pulses of programmable amplitude, frequency (pulses per second), and pulse width. An alternative embodiment entails the use of switching between individual capacitors in an array (switch cap technology) to provide adjacent or overlapping pulses of narrow width to achieve a continuous (or near continuous) pulse of a wider width. The stimulation circuitry is controlled by the microprocessor and is programmable.
- The electrode switching circuitry establishes the function of each electrode and the polarity of the electrode. In the preferred embodiment, the electrode switching circuitry will enable a pair of electrodes to be used for sensing, and a pair or pairs of electrodes to be used for stimulation. FIGS. 6 and 7 depict possible sensing configurations (“pairs”) and possible stimulation vectors for a three and a four electrode system. The stimulation and sensing may utilize the same electrodes. During the stimulation period, the electrode switching circuitry can change the polarity of the stimulation electrodes to create multi-phasic pulses, alternating polarity between pulses or a series of pulses, and different stimulation vectors. Likewise, the switching circuitry can enable different pairs of sensing electrodes to sample gastric electrical activity at various sensing locations or along different vectors. Complex sensing patterns can be invoked to differentiate slow wave propagation direction and intervals. The switching circuitry may also include compensation (to offset internal leakage currents across the switches involved in sensing) and blanking to prevent stimulation pulses from saturating the sense amplifiers. The switching circuitry is controlled by the microprocessor and is programmable. Complex switching schemes can be stored in RAM and be activated as a program. The switching software would be designed to ensure that each configuration would have at least one bipolar pair to complete the electrical circuit.
- The telemetry circuitry consists of an antenna and a transceiver. The circuitry may also include a telemetry buffer to accommodate large data transactions. The telemetry circuit transmits and receives pulses to and from the programmer. The circuitry may employ amplitude modulation, frequency modulation, or pulsed modulation at radio frequencies. In the preferred embodiment, the telemetry would have a range of several inches to allow for deep implantation of the IGS. The telemetry string would utilize an initiation protocol to establish two way communication, an identity packet to provide device/programmer identification, multiple information or programming packets to communicate the requisite data, error checking of the packets (cyclic redundancy checking or check sums) to ensure accuracy of the information, and a termination protocol to signal the end of the string. The incoming string would be processed by the microprocessor to set the parameters of the IGS. The outgoing string would basically acknowledge that the incoming string was accepted, confirm IGS settings or provide raw data/information for processing by the external programmer.
- The RAM is used to store information and programs for the IGS. The RAM receives the sensed information about the intrinsic gastric activity from the microprocessor, analyzes that information to determine if the activity is normal according to a selected algorithm(s), and provides that analysis output to the microprocessor to initiate the therapy in accordance with the particular programming selected. Multiple programs may be stored in RAM to establish specific profiles of IGS activation, response, and performance. The RAM may also be used to store various parameters that indicate device performance, gastric activities, and therapies administered.
- In use, the preferred embodiment of the invention operates as follows:
- The electrodes of the lead(s) would be implanted (laparoscopically or through an open incision) in or on the gastric wall for communication with the circular layer of the gastric smooth muscle (reference FIG. 3). Since the lower portion of the stomach is primarily responsible for solids mixing and motility, the preferred location of the electrodes is the antrum, along the lesser curvature. The lesser curvature is preferable because it does not distend as much as the greater curvature and offers a more stable position. After the lead is secured, the IGS would be connected to the lead(s) and implanted in a subcutaneous or sub-fascial pocket in the patient's abdomen.
- Normal gastric electrical activity progresses caudally from the pacemaker area of the fundus towards the pylorus at a rate of approximately 5 mm per second. The activity tends to speed up and organize as it progresses down the antrum. (FIG. 8 depicts the progression of a normal slow wave along the stomach from position A through position F.) The normal activity has pulse amplitudes, pulse widths, and frequency (intervals) that are discernible from abnormal activity. FIG. 9 depicts the discernible parameters that can be utilized to identify/classify the slow wave.
- As the intrinsic activity crosses an implanted electrode, the depolarization of the cells will impart an electrical potential on that electrode (differentially compared to a second electrode in an area not undergoing depolarization). If the two electrodes have been programmed to serve as sensing electrodes, the electric potential is conveyed to the sensing circuitry. There it is filtered and amplified and presented to the information processor. The information processor (in conjunction with any RAM program/algorithm) identifies/classifies the activity as normal or abnormal. FIG. 10 depicts a string of gastric activity and the potential classification of the waves. If identified as normal, the information processor initiates stimulation as per the programmed parameters. If classified as abnormal, the microprocessor re-initiates sensing. Certain parameters of the intrinsic signal and stimulation are logged into RAM for history and for use in other algorithms.
- An alternative embodiment of the invention analyzes the frequency components of the sensed signal for evidence of electrical response activity resulting from a contraction. If the signal contains frequencies that are associated with a contraction, a stronger type of stimulation is invoked to disrupt/disorganize or decouple the contraction.
- The preferred embodiment may invoke one or multiple stimulation therapies that are dependent upon the activity sensed and the programmed therapeutic scheme. The stimulation may use electrical pulse trains of equally alternating polarity, electrical pulse trains of asymmetrically alternating polarity, and multiphasic pulses of equal or unequal phase widths. The stimulation may be delivered at a single or a plurality of sites. FIG. 11 depicts stimulation at multiple (two) sites. Additionally the stimulation vector can be switched (at any point) between any single pair of electrodes or plurality of electrodes providing that at least one bipolar pair is selected (reference FIGS. 6 and 7). The stimulation schemes are described as follows:
- (a) Stimulation across a slow wave (FIG. 12). Stimulation across a slow wave occurs when the stimulation is applied between electrodes that lie on opposite sides of the slow wave. It is designed to depolarize cells prior to the wave induced depolarization. This will make the cells refractory to the wave and create an attenuation of the slow wave in the area of stimulation. Stimulation across the wave has a disadvantage in that some of the cells involved are already depolarized (as a result of the wave) and energy is wasted on those cells.
- (b) Stimulation in advance (spatial offset) of propagation (FIG. 13). Stimulation in spatial advance of the propagating wave affords the advantage of only involving cells that are not part of the wave. The disadvantage is that the degree (length and direction/orientation) of the spatial offset must be considered to ensure that cell repolarization does not occur before the wave arrives. It may require relatively fixed configurations of electrodes placed in relation to the propagation path.
- (c) Stimulation in advance (spatial and temporal offsets) of propagation (FIG. 14). Stimulation in advance of wave propagation with a temporal and a spatial offset involves sensing at one location and stimulation at a second location with a programmable delay to ensure that the cells do not repolarize before the wave arrives. It affords the advantage of a spatial offset and does not require precise electrode orientations to achieve the same ends.
- (d) Anticipatory (temporal delay to anticipate the next wave) stimulation (FIG. 15). Anticipatory stimulation involves sensing between a pair of electrodes and delaying the stimulation until just prior to the next normal wave is anticipated. The stimulation may be applied to the sensing electrodes or any set of electrodes upstream from the sensing electrodes. The amount of delay is calculated from the history of normal intervals derived from the sensing identification and parameter storage. FIG. 16 depicts a running history used to calculate the expected interval timing until the next normal slow wave. The calculation would involve averaging a running history of normal intervals and subtracting a small time interval from that average. FIG. 17 depicts the anticipatory stimulation interval timing.
- (e) Decoupling stimulation (FIG. 18). Decoupling stimulation involves sensing a peristaltic contraction at one location and strong stimulation at a second location to invoke a competing contraction that would propagate towards and away from the intrinsic contraction. Where the two contractions meet, they would tend to cancel each other. The advancing invoked contraction would not have the volume of chyme because it would precede the intrinsic movement and the efficiency of the gastric motility would be reduced.
- (f) Ectopic stimulation. Ectopic stimulation involves overriding the intrinsic electrical activity by application of strong stimulation at an interval that is shorter than the intrinsic interval and at a location that does not afford a natural progression of the motility. The preferred location is on the gastric antrum close to the pylorus such that the majority of any propagation would be retrograde.
- (g) Combined nerve and gastric stimulation. Combined nerve and gastric stimulation involves application of any of the previously listed therapy schemes with specific stimulation intended to suppress, block, or desensitize the enervation of the stomach. The stimulation could be a combination of pulse trains having neuro and muscular components or separate channels dedicated to the specific neural or muscular waveforms.
- (h) Proportional stimulation. Proportional stimulation is a modulator of any or all of the previous stimulation schemes (except ectopic stimulation). In proportional stimulation, the disruptive, disorganizing, or decoupling stimulation is applied to a programmable percentage of the qualifying (normal) intrinsic activity. FIGS. 19 and 20 depict disorganization of 25% and 50% of the normal slow waves. (An alternative embodiment of FIG. 20 is disorganization of every other normal slow wave.) This type of stimulation allows the physician to modulate the intrinsic activity and still preserve some normal function. In addition, in times of increased abnormal gastric activity (such as when a patient is sick) proportional stimulation will be less frequent due to the decreased quantity of qualifying normal waves.
- It should be recognized that the present invention may be used in many different electrophysiological stimulation embodiments, and all such variations or uses are contemplated by the present invention. While there has been described embodiments of the invention with respect to gastric stimulation and sensing, it will be clear that one skilled in the art may employ such in applications beyond the presently described preferred embodiments. Accordingly, it is intended that the scope of the invention, including such alternatives, modifications, and various shall be defined by the appended claims.
Claims (29)
1. A system for gastric stimulation of a patient comprising:
an implantable gastric stimulator, comprising an information processor, sensing circuitry, electrical stimulation circuitry, electrode switching circuitry, telemetry circuitry, a real time clock, and a power source;
a remote programmer operable with the telemetry circuitry of said implantable gastric stimulator for controlling the operation of the electrical stimulator and sensing circuitry with the information processor;
two or more electrodes for conveying electrical stimulation from the electrical stimulator circuit to the stomach wall of the patient; and
two or more electrodes for conveying sensed gastric electrical activity from the stomach wall to the sensing circuitry of the said implantable gastric stimulator.
2. A system as recited in claim 1 , comprising one or a plurality of elongated lead body sheaths having proximal end connectors for coupling said stimulation and sensing electrodes with said implantable gastric stimulator, the leads of said stimulation and sensing electrodes extending through the elongated lead body sheaths to their distal end, the distal end of the elongated lead body sheaths for electrical communication with the stomach wall of the patient and for positioning said stimulation and sensing electrodes on or in the stomach wall.
3. A system as recited in claim 1 , wherein said plurality of the stimulation and sensing electrodes are positionable at different locations of the stomach wall.
4. A system as recited in claim 1 , wherein the function of the electrodes is controlled by programmable electrode switching circuitry.
5. A system as recited in claim 1 , wherein the telemetry circuitry of said implantable gastric stimulator comprises a radio frequency telemetry transceiver provided for communication with said remote programmer.
6. A system as recited in claim 1 , wherein said information processor comprises a programmable microprocessor or microcontroller.
7. A system as recited in claim 1 , wherein the system may temporarily revert to a power conserve condition at programmable times of the day.
8. A system as recited in claim 1 , wherein said sensing electrodes communicate gastric electrical signals to the sensing circuitry of said implantable gastric stimulator for processing with the information processor for identifying interval, amplitude, and duration of the intrinsic electrical activity.
9. A system as recited in claim 8 , wherein said sensing electrodes communicate gastric electrical signals to the sensing circuitry of said implantable gastric stimulator for processing with the information processor for identifying the frequency spectrum of the intrinsic electrical activity.
10. A system as recited in claim 9 , wherein the information processor analyzes the electrical activity and classifies it as slow wave or peristaltic wave.
11. A system as recited in claim 10 , wherein the information processor analyzes the intrinsic electrical activity and classifies the activity as normal or abnormal.
12. A system as recited in claim 11 , wherein the system may temporarily revert to a power conserve condition in the absence of a programmable threshold of normal electrical activity.
13. A system as recited in claim 12 , wherein the stimulator delivery of electrical stimulation is triggered by electrical activity classified as normal.
14. A system as recited in claim 13 , wherein the stimulator may be programmed to deliver electrical stimulation on all or a percentage of normal events.
15. A system as recited in claim 14 , wherein the electrical stimulation may be delivered across the intrinsic electrical activity.
16. A system as recited in claim 14 , wherein the electrical stimulation may be delivered with a spatial offset to the intrinsic electrical activity.
17. A system as recited in claim 16 , wherein the electrical stimulation may be delivered with a temporal offset to the sensed intrinsic electrical activity.
18. A system as recited in claim 17 , wherein the electrical stimulation may be delivered in anticipation of the next normal electrical activity.
19. A system as recited in claim 18 , wherein the temporal offset is programmable.
20. A system as recited in claim 19 , wherein the temporal delivery of the electrical stimulation is adaptable based upon an algorithm considering a running history of recent predecessor electrical activity events.
21. A system as recited in claim 20 , wherein the polarity of the stimulation electrodes is programmable allowing stimulation between a single pair or a plurality of electrodes.
22. A system as recited in claim 21 , wherein the stimulator may be programmed to switch the polarity of one or a plurality of the various stimulation electrodes to accommodate multiphase stimulation.
23. A system as recited in claim 22 , wherein the electrical stimulation comprises one or a plurality of biphasic pulses programmable within the following parameters, comprising:
pulse amplitude between 0.0 to 15 V or 0.0 to 15 mA;
pulse width between 20 msec to 500 msec;
pulses per event between 1 and 5; and
first phase width between 25 to 100 percent of pulse width.
24. A method for claim 23 , wherein the pulse width is accommodated by switching between two or more capacitors in an array.
25. A system as recited in claim 22 , wherein the electrical stimulation comprises an alternating polarity pulse train programmable within the following parameters, comprising:
pulse amplitude between 0.0 to 15 V or 0.0 to 15 mA; pulse width between 100 μsec and 750 μsec;
pulses per second (frequency) between 10 to 120 Hz; and
duration of pulse train between 0.5 and 30 seconds.
26. A system as recited in claim 25 , wherein parameters comprising quantities, interval frequency, duration, amplitude, or the like for the sensed events and quantities of paced events are stored for subsequent recall.
27. A system as recited in claim 26 , wherein the sensed intrinsic waveforms can be telemetered to the external programmer to assist in establishing the appropriate stimulation parameters.
28. A system as recited in claim 1 , wherein the stimulator may incorporate one or a plurality of independently programmable stimulation or sensing channels.
29. A system as recited in claim 28 , wherein at least one stimulation channel may be programmable to parameters associated with nerve stimulation.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/963,149 US20020072780A1 (en) | 2000-09-26 | 2001-09-25 | Method and apparatus for intentional impairment of gastric motility and /or efficiency by triggered electrical stimulation of the gastrointestinal tract with respect to the intrinsic gastric electrical activity |
US10/782,087 US7941221B2 (en) | 2000-09-26 | 2004-02-19 | Method and apparatus for intentional impairment of gastric motility and/or efficiency by triggered electrical stimulation of the gastrointestinal tract with respect to the intrinsic gastric electrical activity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23566000P | 2000-09-26 | 2000-09-26 | |
US09/963,149 US20020072780A1 (en) | 2000-09-26 | 2001-09-25 | Method and apparatus for intentional impairment of gastric motility and /or efficiency by triggered electrical stimulation of the gastrointestinal tract with respect to the intrinsic gastric electrical activity |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/782,087 Continuation US7941221B2 (en) | 2000-09-26 | 2004-02-19 | Method and apparatus for intentional impairment of gastric motility and/or efficiency by triggered electrical stimulation of the gastrointestinal tract with respect to the intrinsic gastric electrical activity |
Publications (1)
Publication Number | Publication Date |
---|---|
US20020072780A1 true US20020072780A1 (en) | 2002-06-13 |
Family
ID=22886416
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/963,149 Abandoned US20020072780A1 (en) | 2000-09-26 | 2001-09-25 | Method and apparatus for intentional impairment of gastric motility and /or efficiency by triggered electrical stimulation of the gastrointestinal tract with respect to the intrinsic gastric electrical activity |
US10/782,087 Active 2024-09-19 US7941221B2 (en) | 2000-09-26 | 2004-02-19 | Method and apparatus for intentional impairment of gastric motility and/or efficiency by triggered electrical stimulation of the gastrointestinal tract with respect to the intrinsic gastric electrical activity |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/782,087 Active 2024-09-19 US7941221B2 (en) | 2000-09-26 | 2004-02-19 | Method and apparatus for intentional impairment of gastric motility and/or efficiency by triggered electrical stimulation of the gastrointestinal tract with respect to the intrinsic gastric electrical activity |
Country Status (8)
Country | Link |
---|---|
US (2) | US20020072780A1 (en) |
EP (1) | EP1322380A4 (en) |
JP (1) | JP2004509714A (en) |
CN (1) | CN1476339A (en) |
AU (1) | AU2001293039A1 (en) |
CA (1) | CA2421846A1 (en) |
NO (1) | NO20031348L (en) |
WO (1) | WO2002026317A1 (en) |
Cited By (117)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030144708A1 (en) * | 2002-01-29 | 2003-07-31 | Starkebaum Warren L. | Methods and apparatus for retarding stomach emptying for treatment of eating disorders |
US20030167025A1 (en) * | 2001-05-01 | 2003-09-04 | Imran Mir A. | Gastric treatment/diagnosis device and attachment device and method |
US20030181959A1 (en) * | 2002-03-22 | 2003-09-25 | Dobak John D. | Wireless electric modulation of sympathetic nervous system |
US20030181958A1 (en) * | 2002-03-22 | 2003-09-25 | Dobak John D. | Electric modulation of sympathetic nervous system |
WO2003099376A1 (en) * | 2002-05-23 | 2003-12-04 | Transneuronix, Inc. | Improved process and electrostimulation device for treating obesity and/or gastroesophageal reflux disease |
US20040162595A1 (en) * | 2000-09-26 | 2004-08-19 | Transneuronix, Inc. | Method and apparatus for intentional impairment of gastric motility and/or efficiency by triggered electrical stimulation of the gastrointestinal tract with respect to the intrinsic gastric electrical activity |
US20040172086A1 (en) * | 2003-02-03 | 2004-09-02 | Beta Medical, Inc. | Nerve conduction block treatment |
US20040230255A1 (en) * | 2002-03-22 | 2004-11-18 | Dobak John D. | Splanchnic nerve stimulation for treatment of obesity |
US20040267330A1 (en) * | 2003-04-25 | 2004-12-30 | Lee Michael T. | Generation of theraphy programs and program groups |
US20050038484A1 (en) * | 2003-02-03 | 2005-02-17 | Enteromedics, Inc. | Controlled vagal blockage therapy |
US20050065575A1 (en) * | 2002-09-13 | 2005-03-24 | Dobak John D. | Dynamic nerve stimulation for treatment of disorders |
US20050065571A1 (en) * | 2001-05-01 | 2005-03-24 | Imran Mir A. | Responsive gastric stimulator |
US20050090873A1 (en) * | 2003-10-22 | 2005-04-28 | Imran Mir A. | Gastrointestinal stimulation device |
US20050131485A1 (en) * | 2003-02-03 | 2005-06-16 | Enteromedics, Inc. | High frequency vagal blockage therapy |
US20050128187A1 (en) * | 2003-12-12 | 2005-06-16 | Yu-Yu Chen | Computer cursor pointing device with electric stimulator |
US20050137643A1 (en) * | 2003-11-28 | 2005-06-23 | Mintchev Martin P. | Gastrointestinal motility control |
US20050143784A1 (en) * | 2001-05-01 | 2005-06-30 | Imran Mir A. | Gastrointestinal anchor with optimal surface area |
US20050149141A1 (en) * | 2004-01-07 | 2005-07-07 | Starkebaum Warren L. | Gastric stimulation for altered perception to treat obesity |
US20050187597A1 (en) * | 2004-02-25 | 2005-08-25 | Vanderschuit Carl R. | Therapeutic devices and methods for applying therapy |
US20050222638A1 (en) * | 2004-03-30 | 2005-10-06 | Steve Foley | Sensor based gastrointestinal electrical stimulation for the treatment of obesity or motility disorders |
US20050222637A1 (en) * | 2004-03-30 | 2005-10-06 | Transneuronix, Inc. | Tachygastrial electrical stimulation |
US20060020298A1 (en) * | 2004-07-20 | 2006-01-26 | Camilleri Michael L | Systems and methods for curbing appetite |
US20060036293A1 (en) * | 2004-08-16 | 2006-02-16 | Whitehurst Todd K | Methods for treating gastrointestinal disorders |
US20060074457A1 (en) * | 2001-05-01 | 2006-04-06 | Imran Mir A | Pseudounipolar lead for stimulating a digestive organ |
US20060074458A1 (en) * | 2001-05-01 | 2006-04-06 | Imran Mir A | Digestive organ retention device |
US20060074459A1 (en) * | 2000-12-11 | 2006-04-06 | Melina Flesler | Acute and chronic electrical signal therapy for obesity |
US20060070334A1 (en) * | 2004-09-27 | 2006-04-06 | Blue Hen, Llc | Sidewall plank for constructing a trailer and associated trailer sidewall construction |
US20060089699A1 (en) * | 2001-05-01 | 2006-04-27 | Imran Mir A | Abdominally implanted stimulator and method |
US20060190053A1 (en) * | 2002-03-22 | 2006-08-24 | Dobak John D Iii | Neural stimulation for treatment of metabolic syndrome and type 2 diabetes |
US20060235448A1 (en) * | 2005-04-13 | 2006-10-19 | Roslin Mitchell S | Artificial gastric valve |
US20070043411A1 (en) * | 2005-08-17 | 2007-02-22 | Enteromedics Inc. | Neural electrode |
US20070043400A1 (en) * | 2005-08-17 | 2007-02-22 | Donders Adrianus P | Neural electrode treatment |
US20070049986A1 (en) * | 2005-09-01 | 2007-03-01 | Imran Mir A | Randomized stimulation of a gastrointestinal organ |
US20070078494A1 (en) * | 2005-09-23 | 2007-04-05 | Mintchev Martin P | Method and apparatus for controlling motility of gastrointestinal organs for the treatment of obesity |
US20070135857A1 (en) * | 2003-02-03 | 2007-06-14 | Enteromedics, Inc. | GI inflammatory disease treatment |
US20070203521A1 (en) * | 2002-03-22 | 2007-08-30 | Leptos Biomedical, Inc. | Nerve stimulation for treatment of obesity, metabolic syndrome, and type 2 diabetes |
US20070255154A1 (en) * | 2006-04-28 | 2007-11-01 | Medtronic, Inc. | Activity level feedback for managing obesity |
US20070255334A1 (en) * | 2006-04-28 | 2007-11-01 | Medtronic, Inc. | Energy balance therapy for obesity management |
US20070282390A1 (en) * | 2006-06-06 | 2007-12-06 | Shuros Allan C | Amelioration of chronic pain by endolymphatic stimulation |
US20070282387A1 (en) * | 2006-05-17 | 2007-12-06 | Medtronic, Inc. | Electrical stimulation therapy to promote gastric distention for obesity management |
US20070282386A1 (en) * | 2006-06-06 | 2007-12-06 | Shuros Allan C | Method and apparatus for gastrointestinal stimulation via the lymphatic system |
US20080009719A1 (en) * | 2006-06-06 | 2008-01-10 | Shuros Allan C | Method and apparatus for introducing endolymphatic instrumentation |
US20080033511A1 (en) * | 2002-03-22 | 2008-02-07 | Leptos Biomedical, Inc. | Dynamic nerve stimulation employing frequency modulation |
US20080065169A1 (en) * | 2001-05-01 | 2008-03-13 | Intrapace, Inc. | Endoscopic Instrument for Engaging a Device |
US20080097412A1 (en) * | 2006-09-01 | 2008-04-24 | Shuros Allan C | Method and apparatus for endolymphatic drug delivery |
US7371215B2 (en) | 2001-05-01 | 2008-05-13 | Intrapace, Inc. | Endoscopic instrument for engaging a device |
US20080183238A1 (en) * | 2002-07-26 | 2008-07-31 | Medtronic, Inc. | Process for electrostimulation treatment of morbid obesity |
US20080195171A1 (en) * | 2007-02-13 | 2008-08-14 | Sharma Virender K | Method and Apparatus for Electrical Stimulation of the Pancreatico-Biliary System |
US20080262411A1 (en) * | 2006-06-02 | 2008-10-23 | Dobak John D | Dynamic nerve stimulation in combination with other eating disorder treatment modalities |
US20080281365A1 (en) * | 2007-05-09 | 2008-11-13 | Tweden Katherine S | Neural signal duty cycle |
US20080294228A1 (en) * | 2007-05-23 | 2008-11-27 | Cardiac Pacemakers | Method and device for controlled stimulation of lymphatic flow |
US20090018606A1 (en) * | 2005-10-12 | 2009-01-15 | Intrapace, Inc. | Methods and Devices for Stimulation of an Organ with the Use of a Transectionally Placed Guide Wire |
US20090030474A1 (en) * | 2007-06-29 | 2009-01-29 | Intrapace, Inc. | Sensor Driven Gastric Stimulation for Patient Management |
US20090030475A1 (en) * | 2007-07-25 | 2009-01-29 | Intrapace, Inc. | Gastric Stimulation Systems and Methods Utilizing a Transgastric Probe |
CN100469401C (en) * | 2005-10-28 | 2009-03-18 | 清华大学 | Implant nervous electric pulse stimulus system |
US7509175B2 (en) | 2006-08-03 | 2009-03-24 | Intrapace, Inc. | Method and devices for stimulation of an organ with the use of a transectionally placed guide wire |
US20090088819A1 (en) * | 2007-10-01 | 2009-04-02 | Medtronic, Inc. | Gastric electrical stimulation with multi-site stimulation anti-desensitization feature |
US20090118777A1 (en) * | 2007-08-09 | 2009-05-07 | Kobi Iki | Efferent and afferent splanchnic nerve stimulation |
US20090157138A1 (en) * | 2006-04-18 | 2009-06-18 | Electrocore, Inc. | Methods And Apparatus For Treating Ileus Condition Using Electrical Signals |
US20090234417A1 (en) * | 2005-11-10 | 2009-09-17 | Electrocore, Inc. | Methods And Apparatus For The Treatment Of Metabolic Disorders |
US20090259279A1 (en) * | 2002-03-22 | 2009-10-15 | Dobak Iii John D | Splanchnic nerve stimulation for treatment of obesity |
US7623924B2 (en) | 2004-08-31 | 2009-11-24 | Leptos Biomedical, Inc. | Devices and methods for gynecologic hormone modulation in mammals |
US20090312785A1 (en) * | 2008-06-11 | 2009-12-17 | Allergan, Inc. | Implantable Pump System |
US20100057178A1 (en) * | 2006-04-18 | 2010-03-04 | Electrocore, Inc. | Methods and apparatus for spinal cord stimulation using expandable electrode |
US20100076508A1 (en) * | 2008-09-25 | 2010-03-25 | Boston Scientific Neuromodulation Corporation | Electrical stimulation leads having rf compatibility and methods of use and manufacture |
US20100160745A1 (en) * | 2008-12-12 | 2010-06-24 | Intrapace, Inc. | Detection of Food or Drink Consumption In Order to Control Therapy or Provide Diagnostics |
US7756582B2 (en) | 2001-05-01 | 2010-07-13 | Intrapace, Inc. | Gastric stimulation anchor and method |
US20100228313A1 (en) * | 2009-03-03 | 2010-09-09 | Medtronic, Inc. | Electrical stimulation therapy to promote gastric distention for obesity management |
US20100234917A1 (en) * | 2001-05-01 | 2010-09-16 | Intrapace, Inc. | Digestive Organ Retention Device |
US20100268297A1 (en) * | 2009-02-24 | 2010-10-21 | Hans Neisz | Duodenal Stimulation To Induce Satiety |
US7837719B2 (en) | 2002-05-09 | 2010-11-23 | Daemen College | Electrical stimulation unit and waterbath system |
US20100324611A1 (en) * | 2008-12-10 | 2010-12-23 | Waverx, Inc. | Devices, systems and methods for preventing and treating sensation loss |
US20110034760A1 (en) * | 2009-04-03 | 2011-02-10 | Intrapace, Inc. | Feedback systems and methods to enhance obstructive and other obesity treatments |
US20110071589A1 (en) * | 2009-09-21 | 2011-03-24 | Medtronic, Inc. | Waveforms for electrical stimulation therapy |
US20110190844A1 (en) * | 2005-07-29 | 2011-08-04 | Medtronic, Inc. | Transmembrane sensing device for sensing bladder condition |
US20110201875A1 (en) * | 2010-02-12 | 2011-08-18 | Allergan, Inc. | Remotely adjustable gastric banding system |
US20110201874A1 (en) * | 2010-02-12 | 2011-08-18 | Allergan, Inc. | Remotely adjustable gastric banding system |
US20110257760A1 (en) * | 2010-04-15 | 2011-10-20 | Waldrep Donald J | Gastric implant and method for use of same |
US8236023B2 (en) | 2004-03-18 | 2012-08-07 | Allergan, Inc. | Apparatus and method for volume adjustment of intragastric balloons |
US8295926B2 (en) | 2006-06-02 | 2012-10-23 | Advanced Neuromodulation Systems, Inc. | Dynamic nerve stimulation in combination with other eating disorder treatment modalities |
US8308630B2 (en) | 2006-01-04 | 2012-11-13 | Allergan, Inc. | Hydraulic gastric band with collapsible reservoir |
US8317677B2 (en) | 2008-10-06 | 2012-11-27 | Allergan, Inc. | Mechanical gastric band with cushions |
US8321030B2 (en) | 2009-04-20 | 2012-11-27 | Advanced Neuromodulation Systems, Inc. | Esophageal activity modulated obesity therapy |
US8340772B2 (en) | 2009-05-08 | 2012-12-25 | Advanced Neuromodulation Systems, Inc. | Brown adipose tissue utilization through neuromodulation |
US8369943B2 (en) | 2006-06-06 | 2013-02-05 | Cardiac Pacemakers, Inc. | Method and apparatus for neural stimulation via the lymphatic system |
US8377081B2 (en) | 2004-03-08 | 2013-02-19 | Allergan, Inc. | Closure system for tubular organs |
US8382780B2 (en) | 2002-08-28 | 2013-02-26 | Allergan, Inc. | Fatigue-resistant gastric banding device |
US8517915B2 (en) | 2010-06-10 | 2013-08-27 | Allergan, Inc. | Remotely adjustable gastric banding system |
US8630715B2 (en) | 2006-04-12 | 2014-01-14 | Medtronic, Inc. | Rule-based stimulation program search |
US20140072929A1 (en) * | 2003-06-19 | 2014-03-13 | Osstell Ab | Method and arrangement relating to testing objects |
US8698373B2 (en) | 2010-08-18 | 2014-04-15 | Apollo Endosurgery, Inc. | Pare piezo power with energy recovery |
US8758221B2 (en) | 2010-02-24 | 2014-06-24 | Apollo Endosurgery, Inc. | Source reservoir with potential energy for remotely adjustable gastric banding system |
US8764624B2 (en) | 2010-02-25 | 2014-07-01 | Apollo Endosurgery, Inc. | Inductively powered remotely adjustable gastric banding system |
US8825164B2 (en) | 2010-06-11 | 2014-09-02 | Enteromedics Inc. | Neural modulation devices and methods |
US8840541B2 (en) | 2010-02-25 | 2014-09-23 | Apollo Endosurgery, Inc. | Pressure sensing gastric banding system |
US8845513B2 (en) | 2002-08-13 | 2014-09-30 | Apollo Endosurgery, Inc. | Remotely adjustable gastric banding device |
US8876694B2 (en) | 2011-12-07 | 2014-11-04 | Apollo Endosurgery, Inc. | Tube connector with a guiding tip |
US8900117B2 (en) | 2004-01-23 | 2014-12-02 | Apollo Endosurgery, Inc. | Releasably-securable one-piece adjustable gastric band |
US8900118B2 (en) | 2008-10-22 | 2014-12-02 | Apollo Endosurgery, Inc. | Dome and screw valves for remotely adjustable gastric banding systems |
US8905915B2 (en) | 2006-01-04 | 2014-12-09 | Apollo Endosurgery, Inc. | Self-regulating gastric band with pressure data processing |
US8934976B2 (en) | 2004-09-23 | 2015-01-13 | Intrapace, Inc. | Feedback systems and methods to enhance obstructive and other obesity treatments, optionally using multiple sensors |
US8961393B2 (en) | 2010-11-15 | 2015-02-24 | Apollo Endosurgery, Inc. | Gastric band devices and drive systems |
US8961394B2 (en) | 2011-12-20 | 2015-02-24 | Apollo Endosurgery, Inc. | Self-sealing fluid joint for use with a gastric band |
US9011365B2 (en) | 2013-03-12 | 2015-04-21 | Medibotics Llc | Adjustable gastrointestinal bifurcation (AGB) for reduced absorption of unhealthy food |
US9028394B2 (en) | 2010-04-29 | 2015-05-12 | Apollo Endosurgery, Inc. | Self-adjusting mechanical gastric band |
US9044298B2 (en) | 2010-04-29 | 2015-06-02 | Apollo Endosurgery, Inc. | Self-adjusting gastric band |
US9050165B2 (en) | 2010-09-07 | 2015-06-09 | Apollo Endosurgery, Inc. | Remotely adjustable gastric banding system |
US9067070B2 (en) | 2013-03-12 | 2015-06-30 | Medibotics Llc | Dysgeusia-inducing neurostimulation for modifying consumption of a selected nutrient type |
US9192501B2 (en) | 2010-04-30 | 2015-11-24 | Apollo Endosurgery, Inc. | Remotely powered remotely adjustable gastric band system |
US9211207B2 (en) | 2010-08-18 | 2015-12-15 | Apollo Endosurgery, Inc. | Power regulated implant |
US9226840B2 (en) | 2010-06-03 | 2016-01-05 | Apollo Endosurgery, Inc. | Magnetically coupled implantable pump system and method |
US9295573B2 (en) | 2010-04-29 | 2016-03-29 | Apollo Endosurgery, Inc. | Self-adjusting gastric band having various compliant components and/or a satiety booster |
US9456916B2 (en) | 2013-03-12 | 2016-10-04 | Medibotics Llc | Device for selectively reducing absorption of unhealthy food |
US9668690B1 (en) | 2001-05-01 | 2017-06-06 | Intrapace, Inc. | Submucosal gastric implant device and method |
US9950171B2 (en) | 2014-10-31 | 2018-04-24 | Medtronic, Inc. | Paired stimulation pulses based on sensed compound action potential |
US10376694B2 (en) | 2008-10-09 | 2019-08-13 | Virender K. Sharma | Method and apparatus for stimulating the vascular system |
US10603489B2 (en) | 2008-10-09 | 2020-03-31 | Virender K. Sharma | Methods and apparatuses for stimulating blood vessels in order to control, treat, and/or prevent a hemorrhage |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4175662B2 (en) | 1996-01-08 | 2008-11-05 | インパルス ダイナミクス エヌ.ヴイ. | Electric muscle control device |
US9289618B1 (en) | 1996-01-08 | 2016-03-22 | Impulse Dynamics Nv | Electrical muscle controller |
US8825152B2 (en) | 1996-01-08 | 2014-09-02 | Impulse Dynamics, N.V. | Modulation of intracellular calcium concentration using non-excitatory electrical signals applied to the tissue |
US9713723B2 (en) * | 1996-01-11 | 2017-07-25 | Impulse Dynamics Nv | Signal delivery through the right ventricular septum |
US8700161B2 (en) | 1999-03-05 | 2014-04-15 | Metacure Limited | Blood glucose level control |
WO2001091854A1 (en) * | 2000-05-31 | 2001-12-06 | Impulse Dynamics Nv | Electropancreatography |
US9101765B2 (en) | 1999-03-05 | 2015-08-11 | Metacure Limited | Non-immediate effects of therapy |
US8666495B2 (en) | 1999-03-05 | 2014-03-04 | Metacure Limited | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar |
JP4246492B2 (en) * | 2001-01-05 | 2009-04-02 | メタキュアー ナームロゼ フェンノートシャップ | Regulation of eating habits |
AU2002255245A1 (en) | 2001-04-18 | 2002-10-28 | Impulse Dynamics Nv | Analysis of eating habits |
EP1455892A4 (en) * | 2001-11-29 | 2008-03-26 | Metacure N V | Sensing of pancreatic electrical activity |
US6937891B2 (en) | 2002-04-26 | 2005-08-30 | Medtronic, Inc. | Independent therapy programs in an implantable medical device |
CN1787850B (en) | 2003-03-10 | 2015-12-16 | 脉冲动力公司 | For transmitting the signal of telecommunication to revise the apparatus and method of gene expression in heart tissue |
US9931503B2 (en) | 2003-03-10 | 2018-04-03 | Impulse Dynamics Nv | Protein activity modification |
US7502649B2 (en) * | 2003-06-20 | 2009-03-10 | Metacure Ltd. | Gastrointestinal methods and apparatus for use in treating disorders |
US20070060971A1 (en) * | 2003-07-21 | 2007-03-15 | Ofer Glasberg | Hepatic device for treatment or glucose detection |
US8792985B2 (en) | 2003-07-21 | 2014-07-29 | Metacure Limited | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar |
US7931693B2 (en) | 2004-02-26 | 2011-04-26 | Endosphere, Inc. | Method and apparatus for reducing obesity |
US8147561B2 (en) | 2004-02-26 | 2012-04-03 | Endosphere, Inc. | Methods and devices to curb appetite and/or reduce food intake |
US8585771B2 (en) | 2004-02-26 | 2013-11-19 | Endosphere, Inc. | Methods and devices to curb appetite and/or to reduce food intake |
US8548583B2 (en) | 2004-03-10 | 2013-10-01 | Impulse Dynamics Nv | Protein activity modification |
US8352031B2 (en) | 2004-03-10 | 2013-01-08 | Impulse Dynamics Nv | Protein activity modification |
EP1747043A4 (en) | 2004-05-04 | 2008-04-23 | Univ Rochester | Implantable bio-electro-physiologic interface matrix |
WO2006018851A2 (en) | 2004-08-18 | 2006-02-23 | Metacure Ltd. | Monitoring, analysis, and regulation of eating habits |
US9821158B2 (en) | 2005-02-17 | 2017-11-21 | Metacure Limited | Non-immediate effects of therapy |
WO2007080595A2 (en) | 2006-01-12 | 2007-07-19 | Metacure N.V. | Electrode assemblies, tools, and methods for gastric wall implantation |
US20060247717A1 (en) * | 2005-04-28 | 2006-11-02 | Medtronic, Inc. | Electrical stimulation of the gastrointestinal tract to regulate motility |
EP1890763A4 (en) | 2005-06-02 | 2017-05-03 | Metacure Limited | Gi lead implantation |
US8442841B2 (en) | 2005-10-20 | 2013-05-14 | Matacure N.V. | Patient selection method for assisting weight loss |
US8295932B2 (en) | 2005-12-05 | 2012-10-23 | Metacure Limited | Ingestible capsule for appetite regulation |
EP1852143B1 (en) * | 2006-05-03 | 2013-04-10 | Medtronic, Inc. | Electrode for implantation in a living organ |
US9020597B2 (en) | 2008-11-12 | 2015-04-28 | Endostim, Inc. | Device and implantation system for electrical stimulation of biological systems |
WO2007139920A2 (en) * | 2006-05-26 | 2007-12-06 | Endosphere, Inc. | Improvements in methods and devices to curb appetite and/or reduce food intake |
US9060835B2 (en) | 2006-05-26 | 2015-06-23 | Endosphere, Inc. | Conformationally-stabilized intraluminal device for medical applications |
US9345879B2 (en) | 2006-10-09 | 2016-05-24 | Endostim, Inc. | Device and implantation system for electrical stimulation of biological systems |
US9724510B2 (en) | 2006-10-09 | 2017-08-08 | Endostim, Inc. | System and methods for electrical stimulation of biological systems |
US20150224310A1 (en) | 2006-10-09 | 2015-08-13 | Endostim, Inc. | Device and Implantation System for Electrical Stimulation of Biological Systems |
US11577077B2 (en) | 2006-10-09 | 2023-02-14 | Endostim, Inc. | Systems and methods for electrical stimulation of biological systems |
US8417342B1 (en) * | 2007-07-03 | 2013-04-09 | University Of Mississippi Medical Center | Gastrointestinal electrical stimulation device and method for treating gastrointestinal disorders |
US20110137227A1 (en) | 2007-07-16 | 2011-06-09 | Mckinley James T | Methods and devices for delivering or delaying lipids within a duodenum |
WO2011092710A2 (en) | 2010-02-01 | 2011-08-04 | Metacure Limited | Gastrointestinal electrical therapy |
US11717681B2 (en) | 2010-03-05 | 2023-08-08 | Endostim, Inc. | Systems and methods for treating gastroesophageal reflux disease |
US8447404B2 (en) | 2010-03-05 | 2013-05-21 | Endostim, Inc. | Device and implantation system for electrical stimulation of biological systems |
FR2958857B1 (en) * | 2010-04-16 | 2012-06-22 | Inst Nat Rech Inf Automat | DEVICE AND SYSTEM FOR MONITORING THE HUMAN BODY |
CN102049096B (en) * | 2010-12-22 | 2013-07-10 | 重庆邮电大学 | Independent feedback type stomach pace-making device |
EP2696792B8 (en) | 2011-04-14 | 2018-05-23 | Endostim, Inc. | Systems for treating gastroesophageal reflux disease |
AU2012250686B2 (en) * | 2011-05-03 | 2016-11-03 | Endostim, Inc. | Device and implantation system for electrical stimulation of biological systems |
US9925367B2 (en) | 2011-09-02 | 2018-03-27 | Endostim, Inc. | Laparoscopic lead implantation method |
CN102500057B (en) * | 2011-09-28 | 2014-02-26 | 上海交通大学 | Multifunctional implanted gastrointestinal electrical stimulation system |
CN104736197A (en) | 2012-08-23 | 2015-06-24 | 恩多斯提姆公司 | Device and implantation system for electrical stimulation of biological systems |
US9498619B2 (en) | 2013-02-26 | 2016-11-22 | Endostim, Inc. | Implantable electrical stimulation leads |
EP3041564A4 (en) | 2013-09-03 | 2017-03-29 | Endostim, Inc. | Methods and systems of electrode polarity switching in electrical stimulation therapy |
US9919152B2 (en) | 2014-11-05 | 2018-03-20 | Enterastim, Inc. | Conditional gastrointestinal stimulation for improved motility |
US9682234B2 (en) | 2014-11-17 | 2017-06-20 | Endostim, Inc. | Implantable electro-medical device programmable for improved operational life |
US20220062621A1 (en) | 2015-02-24 | 2022-03-03 | Elira, Inc. | Electrical Stimulation-Based Weight Management System |
US9956393B2 (en) | 2015-02-24 | 2018-05-01 | Elira, Inc. | Systems for increasing a delay in the gastric emptying time for a patient using a transcutaneous electro-dermal patch |
US10335302B2 (en) | 2015-02-24 | 2019-07-02 | Elira, Inc. | Systems and methods for using transcutaneous electrical stimulation to enable dietary interventions |
CN115227969A (en) | 2015-02-24 | 2022-10-25 | 伊莱拉股份有限公司 | Method for achieving appetite regulation or improving dietary compliance using electrode patches |
US10765863B2 (en) | 2015-02-24 | 2020-09-08 | Elira, Inc. | Systems and methods for using a transcutaneous electrical stimulation device to deliver titrated therapy |
US10376145B2 (en) | 2015-02-24 | 2019-08-13 | Elira, Inc. | Systems and methods for enabling a patient to achieve a weight loss objective using an electrical dermal patch |
US10864367B2 (en) | 2015-02-24 | 2020-12-15 | Elira, Inc. | Methods for using an electrical dermal patch in a manner that reduces adverse patient reactions |
CA2980482C (en) * | 2015-06-01 | 2023-09-26 | Saluda Medical Pty Ltd | Motor fibre neuromodulation |
CN105521561B (en) * | 2015-12-30 | 2018-06-12 | 宁波贝思转化医学研究中心有限公司 | A kind of closed circuit small intestine electrical stimulation device |
US20180056063A1 (en) | 2016-08-26 | 2018-03-01 | New York Institute Of Technology | Closed loop system for modulating gastric activity and use thereof |
WO2018094207A1 (en) | 2016-11-17 | 2018-05-24 | Endostim, Inc. | Modular stimulation system for the treatment of gastrointestinal disorders |
CN108210017A (en) * | 2018-03-05 | 2018-06-29 | 江秀秀 | A kind of surgical clamp and the method for judging clamped organization type |
US11511105B2 (en) * | 2018-05-18 | 2022-11-29 | Musc Foundation For Research Development | Noninvasive cranial nerve therapy |
CN110064130A (en) * | 2019-04-17 | 2019-07-30 | 上海黎欧生物科技有限公司 | A kind of gall-bladder pacemaker |
US20210290272A1 (en) * | 2020-01-13 | 2021-09-23 | Xiangyang Ma | Customized posterior atlantoaxial reduction fixatorwith screws and rods |
US20230098646A1 (en) * | 2021-09-30 | 2023-03-30 | Massachusetts Institute Of Technology | Neuromodulation devices and related methods |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5188104A (en) * | 1991-02-01 | 1993-02-23 | Cyberonics, Inc. | Treatment of eating disorders by nerve stimulation |
US6327503B1 (en) * | 1997-04-30 | 2001-12-04 | Medtronic, Inc | Method and apparatus for sensing and stimulating gastrointestinal tract on-demand |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2865376A (en) | 1956-03-27 | 1958-12-23 | American Cyanamid Co | Gold plating surgical needles |
US3760812A (en) | 1971-03-19 | 1973-09-25 | Univ Minnesota | Implantable spiral wound stimulation electrodes |
US4444207A (en) | 1981-10-19 | 1984-04-24 | Cordis Corporation | Method of anchoring a temporary cardiac pacing lead |
US4475560A (en) | 1982-04-29 | 1984-10-09 | Cordis Corporation | Temporary pacing lead assembly |
US4524771A (en) | 1982-10-28 | 1985-06-25 | Ethicon Inc. | Multiple curved surgical needle |
KR950000058B1 (en) | 1986-06-12 | 1995-01-09 | 가부시끼가이샤 뮤텍크 | Suturing needle with suture and method of producing the same |
US5059207A (en) | 1990-08-27 | 1991-10-22 | Shah Mrugesh K | Shaped needles for specialized surgical procedures |
US5100431A (en) | 1990-09-27 | 1992-03-31 | Allergan, Inc. | Single stitch suture needle and method |
US5263480A (en) * | 1991-02-01 | 1993-11-23 | Cyberonics, Inc. | Treatment of eating disorders by nerve stimulation |
US5217471A (en) | 1991-05-30 | 1993-06-08 | Burkhart Stephen S | Endoscopic suture knotting instrument |
US5242458A (en) | 1991-10-15 | 1993-09-07 | Ethicon, Inc. | Suture needle holder for endoscopic use |
IT1260485B (en) * | 1992-05-29 | 1996-04-09 | PROCEDURE AND DEVICE FOR THE TREATMENT OF THE OBESITY OF A PATIENT | |
US5292344A (en) * | 1992-07-10 | 1994-03-08 | Douglas Donald D | Percutaneously placed electrical gastrointestinal pacemaker stimulatory system, sensing system, and pH monitoring system, with optional delivery port |
US5388441A (en) | 1992-12-29 | 1995-02-14 | United States Surgical Corporation | Needle curver with automatic feed |
US5423876A (en) | 1993-12-09 | 1995-06-13 | Medtronic, Inc. | Intramuscular lead having improved insertion |
DE4402058C1 (en) | 1994-01-25 | 1995-04-13 | Andreas Dr Med Asch | Implantable temporary electrode cable |
US5489294A (en) | 1994-02-01 | 1996-02-06 | Medtronic, Inc. | Steroid eluting stitch-in chronic cardiac lead |
US5433728A (en) | 1994-03-02 | 1995-07-18 | Kim; Il G. | Surgical needle |
US5484404A (en) | 1994-05-06 | 1996-01-16 | Alfred E. Mann Foundation For Scientific Research | Replaceable catheter system for physiological sensors, tissue stimulating electrodes and/or implantable fluid delivery systems |
US5540730A (en) | 1995-06-06 | 1996-07-30 | Cyberonics, Inc. | Treatment of motility disorders by nerve stimulation |
US5716392A (en) | 1996-01-05 | 1998-02-10 | Medtronic, Inc. | Minimally invasive medical electrical lead |
US5861104A (en) * | 1996-03-28 | 1999-01-19 | Advanced Micro Devices | Trench isolation with rounded top and bottom corners and edges |
US6453199B1 (en) | 1996-04-01 | 2002-09-17 | Valery Ivanovich Kobozev | Electrical gastro-intestinal tract stimulator |
US5690691A (en) * | 1996-05-08 | 1997-11-25 | The Center For Innovative Technology | Gastro-intestinal pacemaker having phased multi-point stimulation |
CA2264831C (en) | 1996-09-05 | 2003-08-12 | The Governors Of The University Of Alberta | Gastro-intestinal electrical pacemaker |
US6026326A (en) * | 1997-01-13 | 2000-02-15 | Medtronic, Inc. | Apparatus and method for treating chronic constipation |
US5836994A (en) * | 1997-04-30 | 1998-11-17 | Medtronic, Inc. | Method and apparatus for electrical stimulation of the gastrointestinal tract |
US6216039B1 (en) * | 1997-05-02 | 2001-04-10 | Medtronic Inc. | Method and apparatus for treating irregular gastric rhythms |
IT1292016B1 (en) | 1997-05-28 | 1999-01-25 | Valerio Cigaina | IMPLANT DEVICE PARTICULARLY FOR ELECTROSTIMULATION AND / OR ELECTRO-REGISTRATION OF ENDOABDOMINAL VISCERS |
US6321124B1 (en) | 1997-05-28 | 2001-11-20 | Transneuronix, Inc. | Implant device for electrostimulation and/or monitoring of endo-abdominal cavity tissue |
IL133902A0 (en) | 1997-07-16 | 2001-04-30 | Impulse Dynamics Ltd | Smooth muscle controller |
US20030054463A1 (en) | 1997-10-24 | 2003-03-20 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US6104955A (en) | 1997-12-15 | 2000-08-15 | Medtronic, Inc. | Method and apparatus for electrical stimulation of the gastrointestinal tract |
US6091992A (en) | 1997-12-15 | 2000-07-18 | Medtronic, Inc. | Method and apparatus for electrical stimulation of the gastrointestinal tract |
IT1301986B1 (en) | 1998-07-31 | 2000-07-20 | Valerio Cigaina | LAPAROSCOPIC FORCEPS FOR SUTURE. |
US7599736B2 (en) | 2001-07-23 | 2009-10-06 | Dilorenzo Biomedical, Llc | Method and apparatus for neuromodulation and physiologic modulation for the treatment of metabolic and neuropsychiatric disease |
US6097984A (en) * | 1998-11-25 | 2000-08-01 | Medtronic, Inc. | System and method of stimulation for treating gastro-esophageal reflux disease |
US6098672A (en) | 1999-01-14 | 2000-08-08 | Kiholm Industries Llc | Method and apparatus for a product recovery system |
US6895278B1 (en) * | 1999-04-14 | 2005-05-17 | Transneuronix, Inc. | Gastric stimulator apparatus and method for use |
US6606523B1 (en) | 1999-04-14 | 2003-08-12 | Transneuronix Inc. | Gastric stimulator apparatus and method for installing |
US6542776B1 (en) | 1999-04-14 | 2003-04-01 | Transneuronix Inc. | Gastric stimulator apparatus and method for installing |
US6510332B1 (en) | 1999-08-30 | 2003-01-21 | Transneuronix, Inc. | Electrode leads for use in laparoscopic surgery |
US6853862B1 (en) | 1999-12-03 | 2005-02-08 | Medtronic, Inc. | Gastroelectric stimulation for influencing pancreatic secretions |
US6600953B2 (en) | 2000-12-11 | 2003-07-29 | Impulse Dynamics N.V. | Acute and chronic electrical signal therapy for obesity |
CN1476339A (en) | 2000-09-26 | 2004-02-18 | 特兰施钮罗尼克斯股份有限公司 | Method and apparatus for treating obesity by electrical stimulation of gastrointestinal tract using sensed activity |
US6591137B1 (en) | 2000-11-09 | 2003-07-08 | Neuropace, Inc. | Implantable neuromuscular stimulator for the treatment of gastrointestinal disorders |
US6615084B1 (en) | 2000-11-15 | 2003-09-02 | Transneuronix, Inc. | Process for electrostimulation treatment of morbid obesity |
US7020531B1 (en) | 2001-05-01 | 2006-03-28 | Intrapace, Inc. | Gastric device and suction assisted method for implanting a device on a stomach wall |
US6678561B2 (en) | 2001-05-23 | 2004-01-13 | Surgical Development Ag | Heartburn and reflux disease treatment apparatus |
US7160258B2 (en) | 2001-06-26 | 2007-01-09 | Entrack, Inc. | Capsule and method for treating or diagnosing the intestinal tract |
US6735477B2 (en) | 2001-07-09 | 2004-05-11 | Robert A. Levine | Internal monitoring system with detection of food intake |
US20040193229A1 (en) | 2002-05-17 | 2004-09-30 | Medtronic, Inc. | Gastric electrical stimulation for treatment of gastro-esophageal reflux disease |
CN1713933A (en) | 2002-07-26 | 2005-12-28 | 特兰施钮罗尼克斯股份有限公司 | Process for electrostimulation treatment of morbid obesity |
US7620454B2 (en) | 2003-05-19 | 2009-11-17 | Medtronic, Inc. | Gastro-electric stimulation for reducing the acidity of gastric secretions or reducing the amounts thereof |
US7742818B2 (en) | 2003-05-19 | 2010-06-22 | Medtronic, Inc. | Gastro-electric stimulation for increasing the acidity of gastric secretions or increasing the amounts thereof |
CA2588727C (en) | 2003-11-28 | 2014-01-14 | University Technologies International Inc. | Gastrointestinal motility control |
US7177693B2 (en) | 2004-01-07 | 2007-02-13 | Medtronic, Inc. | Gastric stimulation for altered perception to treat obesity |
US20050209653A1 (en) | 2004-03-16 | 2005-09-22 | Medtronic, Inc. | Intra-luminal device for gastrointestinal electrical stimulation |
US20050222638A1 (en) | 2004-03-30 | 2005-10-06 | Steve Foley | Sensor based gastrointestinal electrical stimulation for the treatment of obesity or motility disorders |
-
2001
- 2001-09-25 CN CNA018194567A patent/CN1476339A/en active Pending
- 2001-09-25 EP EP01973465A patent/EP1322380A4/en not_active Withdrawn
- 2001-09-25 AU AU2001293039A patent/AU2001293039A1/en not_active Abandoned
- 2001-09-25 US US09/963,149 patent/US20020072780A1/en not_active Abandoned
- 2001-09-25 JP JP2002530146A patent/JP2004509714A/en active Pending
- 2001-09-25 WO PCT/US2001/029892 patent/WO2002026317A1/en active Application Filing
- 2001-09-25 CA CA002421846A patent/CA2421846A1/en not_active Abandoned
-
2003
- 2003-03-25 NO NO20031348A patent/NO20031348L/en not_active Application Discontinuation
-
2004
- 2004-02-19 US US10/782,087 patent/US7941221B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5188104A (en) * | 1991-02-01 | 1993-02-23 | Cyberonics, Inc. | Treatment of eating disorders by nerve stimulation |
US6327503B1 (en) * | 1997-04-30 | 2001-12-04 | Medtronic, Inc | Method and apparatus for sensing and stimulating gastrointestinal tract on-demand |
Cited By (246)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040162595A1 (en) * | 2000-09-26 | 2004-08-19 | Transneuronix, Inc. | Method and apparatus for intentional impairment of gastric motility and/or efficiency by triggered electrical stimulation of the gastrointestinal tract with respect to the intrinsic gastric electrical activity |
US7941221B2 (en) | 2000-09-26 | 2011-05-10 | Medtronic, Inc. | Method and apparatus for intentional impairment of gastric motility and/or efficiency by triggered electrical stimulation of the gastrointestinal tract with respect to the intrinsic gastric electrical activity |
US20060206160A1 (en) * | 2000-11-15 | 2006-09-14 | Transneuronix, Inc. | Process and electrostimulation device for treating obesity and/or gastroesophageal reflux disease |
US7512442B2 (en) * | 2000-12-11 | 2009-03-31 | Metacure N.V. | Acute and chronic electrical signal therapy for obesity |
US20060074459A1 (en) * | 2000-12-11 | 2006-04-06 | Melina Flesler | Acute and chronic electrical signal therapy for obesity |
US7979127B2 (en) | 2001-05-01 | 2011-07-12 | Intrapace, Inc. | Digestive organ retention device |
US20050236277A9 (en) * | 2001-05-01 | 2005-10-27 | Imran Mir A | Aendoscopic instrument system@ |
US20040088023A1 (en) * | 2001-05-01 | 2004-05-06 | Imran Mir A. | Gastric treatment and diagnosis device and method |
US7747322B2 (en) | 2001-05-01 | 2010-06-29 | Intrapace, Inc. | Digestive organ retention device |
US20100234917A1 (en) * | 2001-05-01 | 2010-09-16 | Intrapace, Inc. | Digestive Organ Retention Device |
US7702394B2 (en) | 2001-05-01 | 2010-04-20 | Intrapace, Inc. | Responsive gastric stimulator |
US7689284B2 (en) | 2001-05-01 | 2010-03-30 | Intrapace, Inc. | Pseudounipolar lead for stimulating a digestive organ |
US7643887B2 (en) | 2001-05-01 | 2010-01-05 | Intrapace, Inc. | Abdominally implanted stimulator and method |
US20100305656A1 (en) * | 2001-05-01 | 2010-12-02 | Intrapace, Inc. | Gastric Simulation Anchor and Method |
US20050065571A1 (en) * | 2001-05-01 | 2005-03-24 | Imran Mir A. | Responsive gastric stimulator |
US20090299434A1 (en) * | 2001-05-01 | 2009-12-03 | Intrapace, Inc. | Endoscopic System For Attaching a Device to a Stomach |
US7590452B2 (en) | 2001-05-01 | 2009-09-15 | Intrapace, Inc. | Endoscopic system for attaching a device to a stomach |
US20030167025A1 (en) * | 2001-05-01 | 2003-09-04 | Imran Mir A. | Gastric treatment/diagnosis device and attachment device and method |
US20090149910A1 (en) * | 2001-05-01 | 2009-06-11 | Inrapace, Inc. | Gastric Treatment/Diagnosis Device and Attachment Device and Method |
US20050143784A1 (en) * | 2001-05-01 | 2005-06-30 | Imran Mir A. | Gastrointestinal anchor with optimal surface area |
US7756582B2 (en) | 2001-05-01 | 2010-07-13 | Intrapace, Inc. | Gastric stimulation anchor and method |
US20090099415A1 (en) * | 2001-05-01 | 2009-04-16 | Intrapace, Inc. | Endoscopic Instrument System for Implanting a Device in the Stomach |
US20030164304A1 (en) * | 2001-05-01 | 2003-09-04 | Imran Mir A. | Aendoscopic instrument system@ |
US9668690B1 (en) | 2001-05-01 | 2017-06-06 | Intrapace, Inc. | Submucosal gastric implant device and method |
US20080065169A1 (en) * | 2001-05-01 | 2008-03-13 | Intrapace, Inc. | Endoscopic Instrument for Engaging a Device |
US8019422B2 (en) | 2001-05-01 | 2011-09-13 | Intrapace, Inc. | Gastric device and endoscopic delivery system |
US9517152B2 (en) | 2001-05-01 | 2016-12-13 | Intrapace, Inc. | Responsive gastric stimulator |
US7016735B2 (en) | 2001-05-01 | 2006-03-21 | Intrapace, Inc. | Gastric anchor and method |
US20060069414A1 (en) * | 2001-05-01 | 2006-03-30 | Imran Mir A | Endoscopic instrument system for implanting a device in the stomach |
US20060074457A1 (en) * | 2001-05-01 | 2006-04-06 | Imran Mir A | Pseudounipolar lead for stimulating a digestive organ |
US20060074458A1 (en) * | 2001-05-01 | 2006-04-06 | Imran Mir A | Digestive organ retention device |
US7509174B2 (en) | 2001-05-01 | 2009-03-24 | Intrapace, Inc. | Gastric treatment/diagnosis device and attachment device and method |
US7483754B2 (en) | 2001-05-01 | 2009-01-27 | Intrapace, Inc. | Endoscopic instrument system for implanting a device in the stomach |
US20060089699A1 (en) * | 2001-05-01 | 2006-04-27 | Imran Mir A | Abdominally implanted stimulator and method |
US20090018605A1 (en) * | 2001-05-01 | 2009-01-15 | Intrapace, Inc. | Gastric Treatment/Diagnosis Device and Attachment Device and Method |
US20060116735A1 (en) * | 2001-05-01 | 2006-06-01 | Imran Mir A | Gastric device and endoscopic delivery system |
US7076305B2 (en) | 2001-05-01 | 2006-07-11 | Intrapace, Inc. | Gastric device and instrument system and method |
US8190261B2 (en) | 2001-05-01 | 2012-05-29 | Intrapace, Inc. | Gastrointestinal anchor in optimal surface area |
US7107100B2 (en) | 2001-05-01 | 2006-09-12 | Intrapace, Inc. | Aendoscopic instrument system@ |
US20030167024A1 (en) * | 2001-05-01 | 2003-09-04 | Imran Mir A. | Gastric device and instrument system and method |
US7120498B2 (en) | 2001-05-01 | 2006-10-10 | Intrapace, Inc. | Method and device for securing a functional device to a stomach |
US8239027B2 (en) | 2001-05-01 | 2012-08-07 | Intrapace, Inc. | Responsive gastric stimulator |
US8364269B2 (en) | 2001-05-01 | 2013-01-29 | Intrapace, Inc. | Responsive gastric stimulator |
US7371215B2 (en) | 2001-05-01 | 2008-05-13 | Intrapace, Inc. | Endoscopic instrument for engaging a device |
US20030144708A1 (en) * | 2002-01-29 | 2003-07-31 | Starkebaum Warren L. | Methods and apparatus for retarding stomach emptying for treatment of eating disorders |
US7236822B2 (en) | 2002-03-22 | 2007-06-26 | Leptos Biomedical, Inc. | Wireless electric modulation of sympathetic nervous system |
US20070219596A1 (en) * | 2002-03-22 | 2007-09-20 | Leptos Biomedical, Inc. | Electric modulation of sympathetic nervous sytem |
US20030181958A1 (en) * | 2002-03-22 | 2003-09-25 | Dobak John D. | Electric modulation of sympathetic nervous system |
US20100145408A1 (en) * | 2002-03-22 | 2010-06-10 | Dobak Iii John D | Splanchnic Nerve Stimulation For Treatment of Obesity |
US20100234907A1 (en) * | 2002-03-22 | 2010-09-16 | Dobak Iii John D | Splanchnic Nerve Stimulation for Treatment of Obesity |
US20040230255A1 (en) * | 2002-03-22 | 2004-11-18 | Dobak John D. | Splanchnic nerve stimulation for treatment of obesity |
US7702386B2 (en) | 2002-03-22 | 2010-04-20 | Leptos Biomedical, Inc. | Nerve stimulation for treatment of obesity, metabolic syndrome, and Type 2 diabetes |
US20100249889A1 (en) * | 2002-03-22 | 2010-09-30 | Dobak Iii John D | Neural Stimulation For Treatment of Metabolic Syndrome and Type 2 Diabetes |
US7689277B2 (en) | 2002-03-22 | 2010-03-30 | Leptos Biomedical, Inc. | Neural stimulation for treatment of metabolic syndrome and type 2 diabetes |
US8145299B2 (en) | 2002-03-22 | 2012-03-27 | Advanced Neuromodulation Systems, Inc. | Neural stimulation for treatment of metabolic syndrome and type 2 diabetes |
US8024035B2 (en) | 2002-03-22 | 2011-09-20 | Advanced Neuromodulation Systems, Inc. | Electric modulation of sympathetic nervous system |
US7239912B2 (en) | 2002-03-22 | 2007-07-03 | Leptos Biomedical, Inc. | Electric modulation of sympathetic nervous system |
US20070203521A1 (en) * | 2002-03-22 | 2007-08-30 | Leptos Biomedical, Inc. | Nerve stimulation for treatment of obesity, metabolic syndrome, and type 2 diabetes |
US8340760B2 (en) | 2002-03-22 | 2012-12-25 | Advanced Neuromodulation Systems, Inc. | Electric modulation of sympathetic nervous system |
US20070225768A1 (en) * | 2002-03-22 | 2007-09-27 | Leptos Biomedical, Inc. | Electric modulation of sympathetic nervous system |
US8838231B2 (en) | 2002-03-22 | 2014-09-16 | Advanced Neuromodulation Systems, Inc. | Neural Stimulation for treatment of metabolic syndrome and type 2 diabetes |
US20090259279A1 (en) * | 2002-03-22 | 2009-10-15 | Dobak Iii John D | Splanchnic nerve stimulation for treatment of obesity |
US7937144B2 (en) | 2002-03-22 | 2011-05-03 | Advanced Neuromodulation Systems, Inc. | Electric modulation of sympathetic nervous system |
US20080033511A1 (en) * | 2002-03-22 | 2008-02-07 | Leptos Biomedical, Inc. | Dynamic nerve stimulation employing frequency modulation |
US7937145B2 (en) | 2002-03-22 | 2011-05-03 | Advanced Neuromodulation Systems, Inc. | Dynamic nerve stimulation employing frequency modulation |
US20060190053A1 (en) * | 2002-03-22 | 2006-08-24 | Dobak John D Iii | Neural stimulation for treatment of metabolic syndrome and type 2 diabetes |
US7551964B2 (en) | 2002-03-22 | 2009-06-23 | Leptos Biomedical, Inc. | Splanchnic nerve stimulation for treatment of obesity |
US20030181959A1 (en) * | 2002-03-22 | 2003-09-25 | Dobak John D. | Wireless electric modulation of sympathetic nervous system |
US20100331910A1 (en) * | 2002-05-09 | 2010-12-30 | Daemen College | Electrical stimulation unit and waterbath system |
US7837719B2 (en) | 2002-05-09 | 2010-11-23 | Daemen College | Electrical stimulation unit and waterbath system |
WO2003099376A1 (en) * | 2002-05-23 | 2003-12-04 | Transneuronix, Inc. | Improved process and electrostimulation device for treating obesity and/or gastroesophageal reflux disease |
US20080183238A1 (en) * | 2002-07-26 | 2008-07-31 | Medtronic, Inc. | Process for electrostimulation treatment of morbid obesity |
US8845513B2 (en) | 2002-08-13 | 2014-09-30 | Apollo Endosurgery, Inc. | Remotely adjustable gastric banding device |
US8382780B2 (en) | 2002-08-28 | 2013-02-26 | Allergan, Inc. | Fatigue-resistant gastric banding device |
US7689276B2 (en) | 2002-09-13 | 2010-03-30 | Leptos Biomedical, Inc. | Dynamic nerve stimulation for treatment of disorders |
US20050065575A1 (en) * | 2002-09-13 | 2005-03-24 | Dobak John D. | Dynamic nerve stimulation for treatment of disorders |
US8538533B2 (en) | 2003-02-03 | 2013-09-17 | Enteromedics Inc. | Controlled vagal blockage therapy |
US20110034968A1 (en) * | 2003-02-03 | 2011-02-10 | Enteromedics Inc. | Controlled vagal blockage therapy |
US20040172086A1 (en) * | 2003-02-03 | 2004-09-02 | Beta Medical, Inc. | Nerve conduction block treatment |
US7729771B2 (en) | 2003-02-03 | 2010-06-01 | Enteromedics Inc. | Nerve stimulation and blocking for treatment of gastrointestinal disorders |
US7613515B2 (en) * | 2003-02-03 | 2009-11-03 | Enteromedics Inc. | High frequency vagal blockage therapy |
US7720540B2 (en) | 2003-02-03 | 2010-05-18 | Enteromedics, Inc. | Pancreatitis treatment |
US9174040B2 (en) | 2003-02-03 | 2015-11-03 | Enteromedics Inc. | Nerve stimulation and blocking for treatment of gastrointestinal disorders |
US20070135857A1 (en) * | 2003-02-03 | 2007-06-14 | Enteromedics, Inc. | GI inflammatory disease treatment |
US8046085B2 (en) | 2003-02-03 | 2011-10-25 | Enteromedics Inc. | Controlled vagal blockage therapy |
US7489969B2 (en) | 2003-02-03 | 2009-02-10 | Enteromedics Inc. | Vagal down-regulation obesity treatment |
US20070135858A1 (en) * | 2003-02-03 | 2007-06-14 | Enteromedics, Inc. | Pancreatitis treatment |
US20050131485A1 (en) * | 2003-02-03 | 2005-06-16 | Enteromedics, Inc. | High frequency vagal blockage therapy |
US9586046B2 (en) | 2003-02-03 | 2017-03-07 | Enteromedics, Inc. | Electrode band system and methods of using the system to treat obesity |
US9682233B2 (en) | 2003-02-03 | 2017-06-20 | Enteromedics Inc. | Nerve stimulation and blocking for treatment of gastrointestinal disorders |
US8010204B2 (en) | 2003-02-03 | 2011-08-30 | Enteromedics Inc. | Nerve blocking for treatment of gastrointestinal disorders |
US7630769B2 (en) | 2003-02-03 | 2009-12-08 | Enteromedics Inc. | GI inflammatory disease treatment |
US20070135846A1 (en) * | 2003-02-03 | 2007-06-14 | Enteromedics, Inc. | Vagal obesity treatment |
US7693577B2 (en) | 2003-02-03 | 2010-04-06 | Enteromedics Inc. | Irritable bowel syndrome treatment |
US20070135856A1 (en) * | 2003-02-03 | 2007-06-14 | Enteromedics, Inc. | Bulimia treatment |
US9162062B2 (en) | 2003-02-03 | 2015-10-20 | Enteromedics Inc. | Controlled vagal blockage therapy |
US8862233B2 (en) | 2003-02-03 | 2014-10-14 | Enteromedics Inc. | Electrode band system and methods of using the system to treat obesity |
US8369952B2 (en) | 2003-02-03 | 2013-02-05 | Enteromedics, Inc. | Bulimia treatment |
US8538542B2 (en) | 2003-02-03 | 2013-09-17 | Enteromedics Inc. | Nerve stimulation and blocking for treatment of gastrointestinal disorders |
US20070142870A1 (en) * | 2003-02-03 | 2007-06-21 | Enteromedics, Inc. | Irritable bowel syndrome treatment |
US20060229685A1 (en) * | 2003-02-03 | 2006-10-12 | Knudson Mark B | Method and apparatus for treatment of gastro-esophageal reflux disease (GERD) |
US7844338B2 (en) | 2003-02-03 | 2010-11-30 | Enteromedics Inc. | High frequency obesity treatment |
US7986995B2 (en) | 2003-02-03 | 2011-07-26 | Enteromedics Inc. | Bulimia treatment |
US20080021512A1 (en) * | 2003-02-03 | 2008-01-24 | Enteromedics Inc. | Nerve stimulation and blocking for treatment of gastrointestinal disorders |
US20050038484A1 (en) * | 2003-02-03 | 2005-02-17 | Enteromedics, Inc. | Controlled vagal blockage therapy |
US20040267330A1 (en) * | 2003-04-25 | 2004-12-30 | Lee Michael T. | Generation of theraphy programs and program groups |
US7826901B2 (en) | 2003-04-25 | 2010-11-02 | Medtronic, Inc. | Generation of therapy programs and program groups |
US20070123953A1 (en) * | 2003-04-25 | 2007-05-31 | Medtronic, Inc. | Generation of therapy programs and program groups |
US8068915B2 (en) | 2003-04-25 | 2011-11-29 | Medtronic, Inc. | Generation of therapy programs and program groups |
US20140072929A1 (en) * | 2003-06-19 | 2014-03-13 | Osstell Ab | Method and arrangement relating to testing objects |
US7430450B2 (en) | 2003-10-22 | 2008-09-30 | Intrapace, Inc. | Device and method for treating obesity |
US20100286745A1 (en) * | 2003-10-22 | 2010-11-11 | Intrapace, Inc. | Radially Expandable Gastrointestinal Stimulation Device |
US7676270B2 (en) | 2003-10-22 | 2010-03-09 | Intrapace, Inc. | Radially expandable gastrointestinal stimulation device |
US20050090873A1 (en) * | 2003-10-22 | 2005-04-28 | Imran Mir A. | Gastrointestinal stimulation device |
US7054690B2 (en) | 2003-10-22 | 2006-05-30 | Intrapace, Inc. | Gastrointestinal stimulation device |
US7343201B2 (en) * | 2003-11-28 | 2008-03-11 | University Technologies International Inc. | Gastrointestinal motility control |
US9050464B2 (en) | 2003-11-28 | 2015-06-09 | Uti Limited Partnership | Gastrointestinal motility control |
US20050137643A1 (en) * | 2003-11-28 | 2005-06-23 | Mintchev Martin P. | Gastrointestinal motility control |
US8706231B2 (en) | 2003-11-28 | 2014-04-22 | University Technologies International Inc. | Gastrointestinal motility control |
US20080200964A1 (en) * | 2003-11-28 | 2008-08-21 | University Technologies International Inc. | Gastrointestinal motility control |
US20050128187A1 (en) * | 2003-12-12 | 2005-06-16 | Yu-Yu Chen | Computer cursor pointing device with electric stimulator |
US7193611B2 (en) * | 2003-12-12 | 2007-03-20 | Yu-Yu Chen | Computer cursor pointing device with electric stimulator |
US7177693B2 (en) | 2004-01-07 | 2007-02-13 | Medtronic, Inc. | Gastric stimulation for altered perception to treat obesity |
US20050149141A1 (en) * | 2004-01-07 | 2005-07-07 | Starkebaum Warren L. | Gastric stimulation for altered perception to treat obesity |
US8900117B2 (en) | 2004-01-23 | 2014-12-02 | Apollo Endosurgery, Inc. | Releasably-securable one-piece adjustable gastric band |
US20050187597A1 (en) * | 2004-02-25 | 2005-08-25 | Vanderschuit Carl R. | Therapeutic devices and methods for applying therapy |
US8377081B2 (en) | 2004-03-08 | 2013-02-19 | Allergan, Inc. | Closure system for tubular organs |
US8236023B2 (en) | 2004-03-18 | 2012-08-07 | Allergan, Inc. | Apparatus and method for volume adjustment of intragastric balloons |
US20050222638A1 (en) * | 2004-03-30 | 2005-10-06 | Steve Foley | Sensor based gastrointestinal electrical stimulation for the treatment of obesity or motility disorders |
US20050222637A1 (en) * | 2004-03-30 | 2005-10-06 | Transneuronix, Inc. | Tachygastrial electrical stimulation |
US20060020298A1 (en) * | 2004-07-20 | 2006-01-26 | Camilleri Michael L | Systems and methods for curbing appetite |
US20060036293A1 (en) * | 2004-08-16 | 2006-02-16 | Whitehurst Todd K | Methods for treating gastrointestinal disorders |
US8452407B2 (en) | 2004-08-16 | 2013-05-28 | Boston Scientific Neuromodulation Corporation | Methods for treating gastrointestinal disorders |
US7623924B2 (en) | 2004-08-31 | 2009-11-24 | Leptos Biomedical, Inc. | Devices and methods for gynecologic hormone modulation in mammals |
US9662240B2 (en) | 2004-09-23 | 2017-05-30 | Intrapace, Inc. | Feedback systems and methods to enhance obstructive and other obesity treatments, optionally using multiple sensors |
US8934976B2 (en) | 2004-09-23 | 2015-01-13 | Intrapace, Inc. | Feedback systems and methods to enhance obstructive and other obesity treatments, optionally using multiple sensors |
US9259342B2 (en) | 2004-09-23 | 2016-02-16 | Intrapace, Inc. | Feedback systems and methods to enhance obstructive and other obesity treatments, optionally using multiple sensors |
US20060070334A1 (en) * | 2004-09-27 | 2006-04-06 | Blue Hen, Llc | Sidewall plank for constructing a trailer and associated trailer sidewall construction |
US8251888B2 (en) | 2005-04-13 | 2012-08-28 | Mitchell Steven Roslin | Artificial gastric valve |
US20100274274A1 (en) * | 2005-04-13 | 2010-10-28 | Allergan, Inc. | Artificial gastric valve |
US20060235448A1 (en) * | 2005-04-13 | 2006-10-19 | Roslin Mitchell S | Artificial gastric valve |
US8623042B2 (en) | 2005-04-13 | 2014-01-07 | Mitchell Roslin | Artificial gastric valve |
US8761888B2 (en) * | 2005-07-29 | 2014-06-24 | Medtronic, Inc. | Transmembrane sensing device for sensing bladder condition |
US20110190844A1 (en) * | 2005-07-29 | 2011-08-04 | Medtronic, Inc. | Transmembrane sensing device for sensing bladder condition |
US7672727B2 (en) | 2005-08-17 | 2010-03-02 | Enteromedics Inc. | Neural electrode treatment |
US7822486B2 (en) | 2005-08-17 | 2010-10-26 | Enteromedics Inc. | Custom sized neural electrodes |
US20100094375A1 (en) * | 2005-08-17 | 2010-04-15 | Enteromedics Inc. | Neural electrode treatment |
US8103349B2 (en) | 2005-08-17 | 2012-01-24 | Enteromedics Inc. | Neural electrode treatment |
US20070043411A1 (en) * | 2005-08-17 | 2007-02-22 | Enteromedics Inc. | Neural electrode |
US20070043400A1 (en) * | 2005-08-17 | 2007-02-22 | Donders Adrianus P | Neural electrode treatment |
US8032223B2 (en) | 2005-09-01 | 2011-10-04 | Intrapace, Inc. | Randomized stimulation of a gastrointestinal organ |
US20070049986A1 (en) * | 2005-09-01 | 2007-03-01 | Imran Mir A | Randomized stimulation of a gastrointestinal organ |
US7616996B2 (en) | 2005-09-01 | 2009-11-10 | Intrapace, Inc. | Randomized stimulation of a gastrointestinal organ |
US20100023087A1 (en) * | 2005-09-01 | 2010-01-28 | Intrapace, Inc. | Randomized stimulation of a gastrointestinal organ |
US20070078494A1 (en) * | 2005-09-23 | 2007-04-05 | Mintchev Martin P | Method and apparatus for controlling motility of gastrointestinal organs for the treatment of obesity |
US20090018606A1 (en) * | 2005-10-12 | 2009-01-15 | Intrapace, Inc. | Methods and Devices for Stimulation of an Organ with the Use of a Transectionally Placed Guide Wire |
CN100469401C (en) * | 2005-10-28 | 2009-03-18 | 清华大学 | Implant nervous electric pulse stimulus system |
US20090234417A1 (en) * | 2005-11-10 | 2009-09-17 | Electrocore, Inc. | Methods And Apparatus For The Treatment Of Metabolic Disorders |
US8323180B2 (en) | 2006-01-04 | 2012-12-04 | Allergan, Inc. | Hydraulic gastric band with collapsible reservoir |
US8308630B2 (en) | 2006-01-04 | 2012-11-13 | Allergan, Inc. | Hydraulic gastric band with collapsible reservoir |
US8905915B2 (en) | 2006-01-04 | 2014-12-09 | Apollo Endosurgery, Inc. | Self-regulating gastric band with pressure data processing |
US8630715B2 (en) | 2006-04-12 | 2014-01-14 | Medtronic, Inc. | Rule-based stimulation program search |
US20090157138A1 (en) * | 2006-04-18 | 2009-06-18 | Electrocore, Inc. | Methods And Apparatus For Treating Ileus Condition Using Electrical Signals |
US20100057178A1 (en) * | 2006-04-18 | 2010-03-04 | Electrocore, Inc. | Methods and apparatus for spinal cord stimulation using expandable electrode |
US7558629B2 (en) * | 2006-04-28 | 2009-07-07 | Medtronic, Inc. | Energy balance therapy for obesity management |
US20070255334A1 (en) * | 2006-04-28 | 2007-11-01 | Medtronic, Inc. | Energy balance therapy for obesity management |
US20070255154A1 (en) * | 2006-04-28 | 2007-11-01 | Medtronic, Inc. | Activity level feedback for managing obesity |
US8185206B2 (en) | 2006-05-17 | 2012-05-22 | Medtronic, Inc. | Electrical stimulation therapy to promote gastric distention for obesity management |
US20070282387A1 (en) * | 2006-05-17 | 2007-12-06 | Medtronic, Inc. | Electrical stimulation therapy to promote gastric distention for obesity management |
WO2007136712A3 (en) * | 2006-05-17 | 2008-02-21 | Medtronic Inc | Electrical stimulation therapy to promote gastric distention for obesity management |
US8295926B2 (en) | 2006-06-02 | 2012-10-23 | Advanced Neuromodulation Systems, Inc. | Dynamic nerve stimulation in combination with other eating disorder treatment modalities |
US20080262411A1 (en) * | 2006-06-02 | 2008-10-23 | Dobak John D | Dynamic nerve stimulation in combination with other eating disorder treatment modalities |
US7894906B2 (en) | 2006-06-06 | 2011-02-22 | Cardiac Pacemakers, Inc. | Amelioration of chronic pain by endolymphatic stimulation |
US8897878B2 (en) | 2006-06-06 | 2014-11-25 | Cardiac Pacemakers, Inc. | Method and apparatus for gastrointestinal stimulation via the lymphatic system |
US20070282386A1 (en) * | 2006-06-06 | 2007-12-06 | Shuros Allan C | Method and apparatus for gastrointestinal stimulation via the lymphatic system |
US20100217346A1 (en) * | 2006-06-06 | 2010-08-26 | Shuros Allan C | Method and apparatus for gastrointestinal stimulation via the lymphatic system |
US7734341B2 (en) | 2006-06-06 | 2010-06-08 | Cardiac Pacemakers, Inc. | Method and apparatus for gastrointestinal stimulation via the lymphatic system |
US8126538B2 (en) | 2006-06-06 | 2012-02-28 | Cardiac Pacemakers, Inc. | Method and apparatus for introducing endolymphatic instrumentation |
US20070282390A1 (en) * | 2006-06-06 | 2007-12-06 | Shuros Allan C | Amelioration of chronic pain by endolymphatic stimulation |
US20080009719A1 (en) * | 2006-06-06 | 2008-01-10 | Shuros Allan C | Method and apparatus for introducing endolymphatic instrumentation |
US8369943B2 (en) | 2006-06-06 | 2013-02-05 | Cardiac Pacemakers, Inc. | Method and apparatus for neural stimulation via the lymphatic system |
US7509175B2 (en) | 2006-08-03 | 2009-03-24 | Intrapace, Inc. | Method and devices for stimulation of an organ with the use of a transectionally placed guide wire |
US8905999B2 (en) | 2006-09-01 | 2014-12-09 | Cardiac Pacemakers, Inc. | Method and apparatus for endolymphatic drug delivery |
US20080097412A1 (en) * | 2006-09-01 | 2008-04-24 | Shuros Allan C | Method and apparatus for endolymphatic drug delivery |
US20080195171A1 (en) * | 2007-02-13 | 2008-08-14 | Sharma Virender K | Method and Apparatus for Electrical Stimulation of the Pancreatico-Biliary System |
US9037244B2 (en) | 2007-02-13 | 2015-05-19 | Virender K. Sharma | Method and apparatus for electrical stimulation of the pancreatico-biliary system |
US20080281365A1 (en) * | 2007-05-09 | 2008-11-13 | Tweden Katherine S | Neural signal duty cycle |
US20080294228A1 (en) * | 2007-05-23 | 2008-11-27 | Cardiac Pacemakers | Method and device for controlled stimulation of lymphatic flow |
US20090030474A1 (en) * | 2007-06-29 | 2009-01-29 | Intrapace, Inc. | Sensor Driven Gastric Stimulation for Patient Management |
US8214049B2 (en) | 2007-07-25 | 2012-07-03 | Intrapace Inc. | Gastric stimulation systems and methods utilizing a transgastric probe |
US20090030475A1 (en) * | 2007-07-25 | 2009-01-29 | Intrapace, Inc. | Gastric Stimulation Systems and Methods Utilizing a Transgastric Probe |
US20090118777A1 (en) * | 2007-08-09 | 2009-05-07 | Kobi Iki | Efferent and afferent splanchnic nerve stimulation |
US20090088819A1 (en) * | 2007-10-01 | 2009-04-02 | Medtronic, Inc. | Gastric electrical stimulation with multi-site stimulation anti-desensitization feature |
US7983755B2 (en) | 2007-10-01 | 2011-07-19 | Medtronic, Inc. | Gastric electrical stimulation with multi-site stimulation anti-desensitization feature |
US20090088817A1 (en) * | 2007-10-01 | 2009-04-02 | Medtronic, Inc. | Gastric electrical stimulation with lockout interval anti-desensitization feature |
US9446234B2 (en) * | 2007-10-01 | 2016-09-20 | Medtronic, Inc. | Gastric electrical stimulation with lockout interval anti-desensitization feature |
US8292800B2 (en) | 2008-06-11 | 2012-10-23 | Allergan, Inc. | Implantable pump system |
US20090312785A1 (en) * | 2008-06-11 | 2009-12-17 | Allergan, Inc. | Implantable Pump System |
US20100076508A1 (en) * | 2008-09-25 | 2010-03-25 | Boston Scientific Neuromodulation Corporation | Electrical stimulation leads having rf compatibility and methods of use and manufacture |
US8364279B2 (en) | 2008-09-25 | 2013-01-29 | Boston Scientific Neuromodulation Corporation | Electrical stimulation leads having RF compatibility and methods of use and manufacture |
US8483844B2 (en) | 2008-09-25 | 2013-07-09 | Boston Scientific Neuromodulation Corporation | Electrical stimulation leads having RF compatibility and methods of use and manufacture |
US8317677B2 (en) | 2008-10-06 | 2012-11-27 | Allergan, Inc. | Mechanical gastric band with cushions |
US11517749B2 (en) | 2008-10-09 | 2022-12-06 | Virender K. Sharma | Methods and apparatuses for stimulating blood vessels in order to control, treat, and/or prevent a hemorrhage |
US10603489B2 (en) | 2008-10-09 | 2020-03-31 | Virender K. Sharma | Methods and apparatuses for stimulating blood vessels in order to control, treat, and/or prevent a hemorrhage |
US10376694B2 (en) | 2008-10-09 | 2019-08-13 | Virender K. Sharma | Method and apparatus for stimulating the vascular system |
US8900118B2 (en) | 2008-10-22 | 2014-12-02 | Apollo Endosurgery, Inc. | Dome and screw valves for remotely adjustable gastric banding systems |
US20100324611A1 (en) * | 2008-12-10 | 2010-12-23 | Waverx, Inc. | Devices, systems and methods for preventing and treating sensation loss |
US20100160745A1 (en) * | 2008-12-12 | 2010-06-24 | Intrapace, Inc. | Detection of Food or Drink Consumption In Order to Control Therapy or Provide Diagnostics |
US20100268297A1 (en) * | 2009-02-24 | 2010-10-21 | Hans Neisz | Duodenal Stimulation To Induce Satiety |
US8538532B2 (en) | 2009-03-03 | 2013-09-17 | Medtronic, Inc. | Electrical stimulation therapy to promote gastric distention for obesity management |
US20100228313A1 (en) * | 2009-03-03 | 2010-09-09 | Medtronic, Inc. | Electrical stimulation therapy to promote gastric distention for obesity management |
US8715181B2 (en) | 2009-04-03 | 2014-05-06 | Intrapace, Inc. | Feedback systems and methods for communicating diagnostic and/or treatment signals to enhance obesity treatments |
EP2414032A4 (en) * | 2009-04-03 | 2016-08-10 | Intrapace Inc | Feedback systems and methods for communicating diagnostic and/or treatment signals to enhance obesity treatments |
US20110034760A1 (en) * | 2009-04-03 | 2011-02-10 | Intrapace, Inc. | Feedback systems and methods to enhance obstructive and other obesity treatments |
US20110087076A1 (en) * | 2009-04-03 | 2011-04-14 | Intrapace, Inc. | Feedback systems and methods for communicating diagnostic and/or treatment signals to enhance obesity treatments |
US8321030B2 (en) | 2009-04-20 | 2012-11-27 | Advanced Neuromodulation Systems, Inc. | Esophageal activity modulated obesity therapy |
US8340772B2 (en) | 2009-05-08 | 2012-12-25 | Advanced Neuromodulation Systems, Inc. | Brown adipose tissue utilization through neuromodulation |
US9937344B2 (en) | 2009-09-21 | 2018-04-10 | Medtronic, Inc. | Waveforms for electrical stimulation therapy |
US20110071589A1 (en) * | 2009-09-21 | 2011-03-24 | Medtronic, Inc. | Waveforms for electrical stimulation therapy |
US20110201874A1 (en) * | 2010-02-12 | 2011-08-18 | Allergan, Inc. | Remotely adjustable gastric banding system |
US8678993B2 (en) | 2010-02-12 | 2014-03-25 | Apollo Endosurgery, Inc. | Remotely adjustable gastric banding system |
US20110201875A1 (en) * | 2010-02-12 | 2011-08-18 | Allergan, Inc. | Remotely adjustable gastric banding system |
US8758221B2 (en) | 2010-02-24 | 2014-06-24 | Apollo Endosurgery, Inc. | Source reservoir with potential energy for remotely adjustable gastric banding system |
US8764624B2 (en) | 2010-02-25 | 2014-07-01 | Apollo Endosurgery, Inc. | Inductively powered remotely adjustable gastric banding system |
US8840541B2 (en) | 2010-02-25 | 2014-09-23 | Apollo Endosurgery, Inc. | Pressure sensing gastric banding system |
US20110257760A1 (en) * | 2010-04-15 | 2011-10-20 | Waldrep Donald J | Gastric implant and method for use of same |
US20150351944A1 (en) * | 2010-04-15 | 2015-12-10 | Donald J. Waldrep | Gastric implant and method for use of same |
US9295573B2 (en) | 2010-04-29 | 2016-03-29 | Apollo Endosurgery, Inc. | Self-adjusting gastric band having various compliant components and/or a satiety booster |
US9044298B2 (en) | 2010-04-29 | 2015-06-02 | Apollo Endosurgery, Inc. | Self-adjusting gastric band |
US9028394B2 (en) | 2010-04-29 | 2015-05-12 | Apollo Endosurgery, Inc. | Self-adjusting mechanical gastric band |
US9192501B2 (en) | 2010-04-30 | 2015-11-24 | Apollo Endosurgery, Inc. | Remotely powered remotely adjustable gastric band system |
US9226840B2 (en) | 2010-06-03 | 2016-01-05 | Apollo Endosurgery, Inc. | Magnetically coupled implantable pump system and method |
US8517915B2 (en) | 2010-06-10 | 2013-08-27 | Allergan, Inc. | Remotely adjustable gastric banding system |
US9358395B2 (en) | 2010-06-11 | 2016-06-07 | Enteromedics Inc. | Neural modulation devices and methods |
US9968778B2 (en) | 2010-06-11 | 2018-05-15 | Reshape Lifesciences Inc. | Neural modulation devices and methods |
US8825164B2 (en) | 2010-06-11 | 2014-09-02 | Enteromedics Inc. | Neural modulation devices and methods |
US9211207B2 (en) | 2010-08-18 | 2015-12-15 | Apollo Endosurgery, Inc. | Power regulated implant |
US8698373B2 (en) | 2010-08-18 | 2014-04-15 | Apollo Endosurgery, Inc. | Pare piezo power with energy recovery |
US9050165B2 (en) | 2010-09-07 | 2015-06-09 | Apollo Endosurgery, Inc. | Remotely adjustable gastric banding system |
US8961393B2 (en) | 2010-11-15 | 2015-02-24 | Apollo Endosurgery, Inc. | Gastric band devices and drive systems |
US8876694B2 (en) | 2011-12-07 | 2014-11-04 | Apollo Endosurgery, Inc. | Tube connector with a guiding tip |
US8961394B2 (en) | 2011-12-20 | 2015-02-24 | Apollo Endosurgery, Inc. | Self-sealing fluid joint for use with a gastric band |
US9067070B2 (en) | 2013-03-12 | 2015-06-30 | Medibotics Llc | Dysgeusia-inducing neurostimulation for modifying consumption of a selected nutrient type |
US9456916B2 (en) | 2013-03-12 | 2016-10-04 | Medibotics Llc | Device for selectively reducing absorption of unhealthy food |
US9011365B2 (en) | 2013-03-12 | 2015-04-21 | Medibotics Llc | Adjustable gastrointestinal bifurcation (AGB) for reduced absorption of unhealthy food |
US9950171B2 (en) | 2014-10-31 | 2018-04-24 | Medtronic, Inc. | Paired stimulation pulses based on sensed compound action potential |
Also Published As
Publication number | Publication date |
---|---|
CA2421846A1 (en) | 2002-04-04 |
WO2002026317A8 (en) | 2002-07-11 |
NO20031348D0 (en) | 2003-03-25 |
CN1476339A (en) | 2004-02-18 |
AU2001293039A1 (en) | 2002-04-08 |
EP1322380A4 (en) | 2009-06-03 |
NO20031348L (en) | 2003-05-23 |
EP1322380A1 (en) | 2003-07-02 |
WO2002026317A1 (en) | 2002-04-04 |
US20040162595A1 (en) | 2004-08-19 |
JP2004509714A (en) | 2004-04-02 |
US7941221B2 (en) | 2011-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7941221B2 (en) | Method and apparatus for intentional impairment of gastric motility and/or efficiency by triggered electrical stimulation of the gastrointestinal tract with respect to the intrinsic gastric electrical activity | |
US6091992A (en) | Method and apparatus for electrical stimulation of the gastrointestinal tract | |
EP1357971B1 (en) | Regulation of eating habits | |
US6615084B1 (en) | Process for electrostimulation treatment of morbid obesity | |
US8494637B2 (en) | Systems and methods for implantable leadless gastrointestinal tissue stimulation | |
US10376694B2 (en) | Method and apparatus for stimulating the vascular system | |
US20080086180A1 (en) | Techniques for gall bladder stimulation | |
US9037244B2 (en) | Method and apparatus for electrical stimulation of the pancreatico-biliary system | |
US5716385A (en) | Crural diaphragm pacemaker and method for treating esophageal reflux disease | |
US6115635A (en) | Method and apparatus for electrical stimulation of the gastrointestinal tract | |
US7738961B2 (en) | Method and apparatus for treatment of the gastrointestinal tract | |
US5540730A (en) | Treatment of motility disorders by nerve stimulation | |
US20040193229A1 (en) | Gastric electrical stimulation for treatment of gastro-esophageal reflux disease | |
US20030144708A1 (en) | Methods and apparatus for retarding stomach emptying for treatment of eating disorders | |
US20080132962A1 (en) | System and method for affecting gatric functions | |
US20040015201A1 (en) | Process for electrostimulation treatment of obesity | |
WO1999003532A2 (en) | Apparatus for treatment of gastric arrhythmias | |
US20070078494A1 (en) | Method and apparatus for controlling motility of gastrointestinal organs for the treatment of obesity | |
Lönroth et al. | Laparoscopic and open placement of electronic implants for gastric electrical stimulation (GES): technique and results |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: TRANSNEURONIX, INC., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FOLEY, STEPHEN T.;REEL/FRAME:012537/0740 Effective date: 20011211 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |